Streck Blood Collection Tubes for ctDNA Stability: A Research and Drug Development Guide

Abstract

This article provides a comprehensive analysis of Streck Cell-Free DNA BCT® tubes for stabilizing circulating tumor DNA (ctDNA) in liquid biopsy workflows. Aimed at researchers, scientists, and drug development professionals, it covers the foundational science behind sample stabilization, outlines methodological applications for reliable ctDNA analysis, addresses troubleshooting and protocol optimization, and presents comparative validation data against other collection tubes. The content synthesizes current research to offer evidence-based guidance for minimizing pre-analytical variation, which is critical for the robust performance of sensitive downstream assays in oncology research and clinical trial contexts.

The Critical Role of Pre-analytical Stability in ctDNA Analysis

Circulating tumor DNA (ctDNA), a subset of cell-free DNA (cfDNA) derived from tumor cells, has emerged as a transformative biomarker in oncology. It enables non-invasive liquid biopsies for cancer diagnosis, monitoring treatment response, detecting minimal residual disease, and identifying therapy-resistant mutations [1]. However, the reliable detection of ctDNA is fraught with pre-analytical challenges, primarily due to its low abundance in the bloodstream. In early-stage cancers, ctDNA can be present at mutant allele frequencies of 0.01% or lower, meaning it is vastly outnumbered by wild-type DNA [2]. Two fundamental pre-analytical problems—ctDNA degradation and genomic DNA (gDNA) contamination—can severely compromise the sensitivity and accuracy of downstream molecular analyses, potentially leading to false-negative or false-positive results [3] [4]. This application note examines the sources and impacts of these challenges and demonstrates how specialized blood collection tubes, such as the Streck Cell-Free DNA BCT, are critical for ensuring sample integrity in clinical and research settings.

The Fundamental Challenges in ctDNA Analysis

The Problem of Genomic DNA Contamination

The most significant pre-analytical challenge is the dilution of the ctDNA signal by wild-type genomic DNA released from white blood cells (WBCs). This process begins soon after blood collection due to the lysis of WBCs.

• Mechanism of Contamination: After venipuncture, white blood cells undergo apoptosis and necrosis, releasing their high-molecular-weight genomic DNA into the plasma fraction [5] [3]. This release is not synchronized with hemolysis, meaning gDNA contamination can occur independently of visible red blood cell lysis [5].
• Impact on Detection Sensitivity: The amount of wild-type gDNA can increase by an order of magnitude or more when blood is stored in standard K₂EDTA tubes for over 6 to 24 hours [6] [7] [2]. This massive influx of wild-type DNA dilutes the already scarce ctDNA fragments, effectively lowering the mutant allele frequency and making detection of true somatic mutations more difficult, even with highly sensitive technologies like digital PCR or next-generation sequencing [2].

The Problem of ctDNA Degradation

The inherent instability of cfDNA in blood presents a second major hurdle.

• Origin and Instability: ctDNA originates from tumor cells through apoptosis and necrosis, resulting in short, fragmented DNA of about 166 base pairs in length [3]. These fragments are susceptible to degradation by nucleases present in the blood, with a reported half-life of approximately 16 minutes [3].
• Consequence for Analysis: Degradation can reduce the overall yield of ctDNA. More critically, repeated freeze-thaw cycles of plasma can cause a shift in the fragment size profile, degrading larger fragments towards smaller sizes, which may affect the representativeness of the sample [3].

Table 1: Key Challenges in ctDNA Analysis and Their Impacts

Challenge	Primary Cause	Consequence on Analysis
gDNA Contamination	Lysis of white blood cells during sample storage [5] [3]	Dilution of mutant allele frequency, reduced detection sensitivity, potential false negatives [2]
ctDNA Degradation	Nuclease activity in the bloodstream; improper sample handling [3]	Reduced total ctDNA yield; altered fragment size profiles; potential loss of tumor-specific information [3]

Comparative Performance of Blood Collection Tubes

The choice of blood collection tube is a critical determinant in mitigating gDNA contamination and preserving ctDNA integrity. Standard K₂EDTA tubes offer no stabilization and require plasma separation within 4 to 6 hours of blood draw to prevent significant gDNA release [6] [8]. Cell-stabilizing tubes, such as those from Streck and Roche, contain proprietary reagents that preserve WBC integrity and inhibit nuclease activity, enabling room-temperature storage for extended periods.

Independent studies have quantitatively compared the performance of these tubes. The data below show that while K₂EDTA tubes fail rapidly, specialized tubes maintain sample stability, with performance nuances between brands.

Table 2: Quantitative Comparison of Blood Collection Tube Performance

Tube Type	Stability Claim	Experimental Findings (gDNA Contamination)	Experimental Findings (cfDNA Concentration)
K₂EDTA Tube	4-6 hours [6]	Severe WBC lysis and gDNA contamination after 7 days [5]. Order of magnitude increase in genome equivalents after 7 days [7].	N/A
Streck cfDNA BCT	Up to 14 days at 6°C-37°C [9]	Consistent cfDNA yield and gDNA levels for at least 3 days; effective stabilization for up to 7-14 days in multiple studies [5] [6] [2]. No significant increase in gDNA after 3 days in patient samples [6].	No significant difference from Day 0 baseline at Day 3 and Day 7 in healthy donors [8].
Roche Cell-Free DNA Tube	Up to 7 days at 15°C-30°C [10]	More capable than Streck and BD tubes at preventing contamination within 14 days in one study [5]. Suitable for less than 7 days [8].	Significant difference from Day 0 baseline observed at Day 7, 10, and 14 in healthy donors [8].

Diagram 1: The impact of blood collection tube choice on pre-analytical challenges and downstream outcomes.

Detailed Experimental Protocol: Evaluating Tube Performance

The following protocol, adapted from published studies, outlines a standard methodology for comparing the performance of different blood collection tubes in stabilizing cfDNA and preventing gDNA contamination [5] [8].

Materials and Equipment

• Blood Collection Tubes: Streck Cell-Free DNA BCT (RUO, Item # 218962), Roche Cell-Free DNA Collection Tube (RUO, Catalog # 07785674001), and K₂EDTA tubes (e.g., BD Vacutainer 367527) for baseline control.
• Participants: Healthy donors or cancer patients (with appropriate ethical approval and informed consent).
• Centrifuges: Equipped with a swing-out rotor and temperature control (4°C).
• Plasma Preparation: 15 mL centrifuge tubes.
• DNA Extraction Kit: QIAamp Circulating Nucleic Acid Kit (Qiagen).
• DNA Quantification: Qubit Fluorometer with dsDNA HS Assay Kit or quantitative PCR (qPCR) assay (e.g., targeting LINE-1 elements).
• Fragment Analysis: Agilent 2100 Bioanalyzer with High Sensitivity DNA Kit.

Procedure

• Blood Collection and Storage:

  • Draw venous blood from each donor into the different tube types (K₂EDTA, Streck, Roche) according to manufacturer instructions, ensuring correct fill volume.
  • Invert each tube 10 times gently to mix the stabilizer.
  • Store all tubes upright at room temperature (e.g., 22-25°C).

• Plasma Processing at Time Points:

  • Process tubes in batches at predefined time points (e.g., 2 hours for K₂EDTA baseline, and Day 3, 7, 10, and 14 for stabilized tubes).
  • First Centrifugation: Centrifuge tubes at 1,600 × g for 10 minutes at room temperature. Use a smooth braking profile to avoid disturbing the buffy coat.
  • Carefully transfer the supernatant (plasma) to a new 15 mL tube, leaving about 500 µL above the buffy coat.
  • Second Centrifugation: Centrifuge the plasma again at 16,000 × g for 10 minutes at 4°C to remove any remaining cellular debris.
  • Transfer the clarified plasma into cryotubes, leaving the bottom pellet undisturbed. Aliquot and store plasma at -80°C.

• cfDNA Extraction and Quantification:

  • Extract cfDNA from a fixed plasma volume (e.g., 2-4 mL) using the QIAamp Circulating Nucleic Acid Kit, following the manufacturer's protocol.
  • Elute the DNA in a small volume (e.g., 35-50 µL) of elution buffer or nuclease-free water.
  • Quantify the total DNA yield using the Qubit Fluorometer.
  • For more precise quality assessment, perform qPCR with two amplicons:
    • A short amplicon (e.g., 96 bp for LINE-1) to quantify fragmented cfDNA.
    • A long amplicon (e.g., 402 bp for LINE-1) to quantify high-molecular-weight gDNA contamination. A high ratio of long-to-short amplicon indicates significant gDNA contamination [6].

• Fragment Size Profiling:

  • Analyze the eluted DNA using the Agilent Bioanalyzer to generate an electrophoretogram.
  • A high-quality cfDNA sample will show a dominant peak at ~165 bp. Contamination by gDNA from WBC lysis is indicated by a smear or a peak of high-molecular-weight DNA.

Diagram 2: A generalized workflow for evaluating blood collection tube performance.

Research Reagent Solutions for ctDNA Stabilization

The following table details key materials and reagents essential for conducting pre-analytical stability research, as cited in the studies reviewed.

Table 3: Essential Research Reagents for ctDNA Pre-Analytical Studies

Item	Function/Description	Example Product & Catalog Number
Stabilizing Blood Collection Tubes	Prevents WBC lysis and stabilizes nucleated cells for up to 14 days, enabling room-temperature transport and storage.	Streck Cell-Free DNA BCT (RUO, #218962) [9], Roche Cell-Free DNA Collection Tube (RUO, #07785674001) [10]
Standard Control Tubes	Provides a baseline for comparison; demonstrates rapid gDNA release without stabilization.	BD Vacutainer K₂EDTA Tube (#367527) [5]
cfDNA Extraction Kit	Isulates circulating nucleic acids from plasma samples efficiently.	QIAamp Circulating Nucleic Acid Kit (Qiagen) [5] [6]
DNA Quantification (Fluorometry)	Provides highly sensitive, dye-based quantification of double-stranded DNA yield.	Qubit Fluorometer with dsDNA HS Assay Kit [8]
DNA Quantification (qPCR)	Quantifies total cfDNA and assesses gDNA contamination via long and short amplicon ratios.	LINE-1 qPCR Assay (96 bp & 402 bp amplicons) [6] [2]
Fragment Size Analyzer	Provides precise fragment size distribution profile to assess cfDNA quality and gDNA contamination.	Agilent 2100 Bioanalyzer with High Sensitivity DNA Kit [8] [2]

The journey of a liquid biopsy sample from the patient to the sequencing instrument is critically dependent on the very first step: blood collection. The challenges of gDNA contamination and ctDNA degradation are not merely theoretical but represent significant practical barriers to achieving the sensitivity required for modern oncology applications, especially in early-stage cancer and minimal residual disease monitoring [2] [1]. As demonstrated, standard K₂EDTA tubes are insufficient for any protocol that involves sample shipping or delayed processing.

Data from controlled studies consistently show that specialized blood collection tubes, such as the Streck Cell-Free DNA BCT, effectively stabilize blood cells and preserve the integrity of the original cfDNA population for several days at room temperature [6] [7] [2]. This capability is paramount for standardizing pre-analytical workflows in multi-center clinical trials and routine diagnostic testing, ensuring that the results of powerful liquid biopsy assays are both reliable and accurate. By mitigating these fundamental pre-analytical challenges, researchers and clinicians can fully leverage the potential of ctDNA to revolutionize cancer patient management.

Within the context of liquid biopsy and circulating tumor DNA (ctDNA) research, the pre-analytical phase is a critical determinant of data reliability. The integrity of delicate analytes such as cell-free DNA (cfDNA), cell-free RNA (cfRNA), and circulating tumor cells (CTCs) can be compromised by factors like white blood cell lysis and nuclease activity between blood collection and processing [11] [8]. Streck blood collection tubes (BCTs) are engineered to mitigate these risks, providing a stabilization solution that enables room-temperature shipment and storage, thereby reducing pre-analytical variation and facilitating batch processing in research and drug development [12]. This application note details the stabilization mechanisms of Streck tubes and provides validated protocols for their use in ctDNA stability research.

The Core Stabilization Mechanism

Streck tubes contain a proprietary, non-toxic preservative reagent that operates through chemical cross-linking to maintain sample integrity [13]. The primary mechanism is not focused on the cell-free analytes themselves, but on the vast population of nucleated blood cells collected in the tube.

The reagent permeates blood cells and introduces stable, intra-strand cross-links into cellular DNA and RNA. These cross-links do not alter the primary sequence of the nucleic acids, which remains accessible for downstream molecular analysis [11]. However, this cross-linking has two critical effects:

• Halts Cellular Metabolism and Apoptosis: The process effectively puts cells into a state of suspended animation, preventing them from initiating programmed cell death (apoptosis) and subsequent lysis [13].
• Prevents Genomic DNA Release: By stabilizing the cells and their nuclear contents, the reagent drastically reduces the release of high-molecular-weight genomic DNA (gDNA) from white blood cells into the plasma [9] [8].

This mechanism is crucial because the major challenge in ctDNA analysis is the preservation of the native cell-free DNA profile. In conventional EDTA tubes, white blood cells lyse over time, releasing a massive amount of background gDNA that can dilute the already scarce tumor-derived fragments and confound mutation detection [11] [8]. By preventing cell lysis, Streck tubes maintain the in vivo concentration of cfDNA and minimize gDNA contamination, ensuring that the isolated material truly represents the original circulating nucleic acid population. The following diagram illustrates this core stabilizing mechanism and its benefits for analysis.

Streck Tube Portfolio and Performance Data

Streck offers a portfolio of tubes tailored to stabilize different analyte classes. The table below summarizes the key performance characteristics of the primary tubes used in liquid biopsy research.

Table 1: Streck Blood Collection Tube Portfolio for Liquid Biopsy

Product Name	Primary Analytes Stabilized	Claimed Stability Duration & Conditions	Key Research Applications
Cell-Free DNA BCT [9]	Cell-free DNA (cfDNA), Circulating Tumor Cells (CTCs)	cfDNA: 14 days (6°C-37°C)\nCTCs: 7 days (15°C-30°C)	ctDNA mutation detection, CTC analysis, NGS, dPCR.
Nucleic Acid BCT [14]	Cell-free DNA, Cell-free RNA, Extracellular Vesicles	7 days at room temperature	Multi-analyte workflows (e.g., cfDNA + cfRNA), exosome research.
Protein Plus BCT [15] [16]	Plasma Proteins, microRNA (miRNA)	5 days at ambient temperature *	Protein biomarker analysis, miRNA cancer biomarker research.
Streck Urine Preserve [15]	Cell-free DNA in urine	7 days (6°C-37°C)	Liquid biopsy from urine samples.

*These performance characteristics have not been evaluated by the U.S. Food & Drug Administration. All products listed are For Research Use Only. Not for use in diagnostic procedures. [15] [9]

Independent studies have validated the performance of Streck tubes against other commercially available options. The following table synthesizes key quantitative findings from comparative studies.

Table 2: Comparative Performance Data from Independent Studies

Study Focus & Tubes Compared	Key Quantitative Findings	Conclusion
gDNA Contamination & cfDNA Stability [8](Streck cfDNA BCT vs. Roche cfDNA Tube)	- No significant difference in median cfDNA concentration between tubes over 14 days (p=0.26).- Significant increase in cfDNA in Roche tubes on days 7, 10, 14 vs. day 0 (p=0.01, 0.046, 0.0016).- No significant change in Streck tubes from day 0 to day 14.	Roche tubes are suitable for room-temperature storage for less than 7 days, while Streck tubes maintain stability for the full 14-day claim.
Mutation Detection Sensitivity [17] [18](Streck vs. Roche vs. Qiagen)	- Mutant DNA (1-3 ng) was reliably detectable in all tubes after 7 days.- For low spike-in levels (0.5 ng), mutation (EGFR T790M) was detected using Roche and Qiagen tubes.	All tubes are highly suitable, though tubes from Roche and Qiagen may allow for detection of slightly lower ctDNA concentrations.
miRNA Recovery [16](Streck Nucleic Acid BCT & Protein Plus BCT vs. EDTA)	- Nucleic Acid BCT and Protein Plus BCT better maintained draw-time plasma miRNA levels over 5 days compared to conventional anticoagulants (EDTA, ACD-A, citrate).	The choice of blood collection tube significantly impacts miRNA recovery, with Streck stabilization tubes providing superior performance for RNA analytes.
Automated cfDNA Extraction Yield [13](Streck vs. K₂EDTA vs. PAXgene vs. Norgen)	- At time 0 (immediate processing), Streck tubes yielded the highest average cfDNA concentration (2.74 ng/mL plasma).- After 168 hours (7 days), Streck cfDNA yield decreased by only 13.1%, while K₂EDTA samples saw a massive increase (68.19 ng/mL) indicating severe gDNA contamination.	Streck tubes provide high, stable cfDNA yield over time with minimal gDNA contamination, making them robust for automated workflows.

Detailed Experimental Protocols

Protocol: Validating cfDNA Stability in Cell-Free DNA BCT

This protocol is designed to verify the stability of cfDNA and the suppression of gDNA contamination in Streck Cell-Free DNA BCTs over a 14-day period at room temperature, as referenced in independent studies [8].

The Scientist's Toolkit:

• Blood Collection Tubes: Streck Cell-Free DNA BCT (RUO, 10 mL) [9].
• Plasma Processing: Refrigerated centrifuge capable of 1600-2000 rcf and 16,000 rcf.
• DNA Extraction Kit: QIAamp Circulating Nucleic Acid Kit (Qiagen) or equivalent [8] [13].
• DNA Quantification: Fluorometer (e.g., Qubit dsDNA HS Assay) [8] [13].
• DNA Quality/Fragment Analysis: Capillary Electrophoresis System (e.g., Agilent 2100 Bioanalyzer with High Sensitivity DNA Kit) [8] [13].

Workflow:

• Collection: Collect venous whole blood from healthy donors or patients directly into Streck Cell-Free DNA BCTs. Invert the tubes 10 times immediately after draw to ensure proper mixing with the preservative [16].
• Storage: Store the filled tubes upright at room temperature (e.g., 22°C ± 2°C). Do not refrigerate or freeze.
• Plasma Isolation (Double-Spin Centrifugation): Process tubes in batches at pre-defined time points (e.g., Day 0, 1, 3, 5, 7, 10, 14).
  • First Spin (Cell Removal): Centrifuge at 1600-2000 rcf for 10 minutes at room temperature. Use low brake settings to avoid disturbing the cell pellet [8].
  • Plasma Transfer: Carefully transfer the supernatant (plasma) to a new centrifuge tube, avoiding the buffy coat and any cellular material.
  • Second Spin (Platelet Removal): Centrifuge the plasma at 16,000 rcf for 10 minutes at 4°C to remove any remaining platelets and debris [11].
  • Final Plasma Aliquot: Transfer the clarified plasma into fresh tubes for immediate DNA extraction or storage at -80°C.
• cfDNA Extraction: Extract cfDNA from a fixed volume of plasma (e.g., 4 mL) using the QIAamp Circulating Nucleic Acid Kit according to the manufacturer's instructions. Elute in a small volume (e.g., 35-50 µL) of nuclease-free water or provided elution buffer [8].
• Analysis:
  • Quantification: Measure the concentration of extracted DNA (in ng/µL) using the Qubit Fluorometer and dsDNA HS Assay.
  • Fragment Analysis: Analyze the eluted DNA using the Bioanalyzer. The electropherogram should show a dominant peak at ~165 bp, characteristic of cfDNA. The absence of a high-molecular-weight smear (>1000 bp) indicates successful suppression of gDNA contamination.

The following workflow diagram visualizes this multi-step protocol.

Protocol: Evaluating miRNA Stability in Nucleic Acid BCT

This protocol, based on Streck's presented research, assesses the stability of cell-free miRNA in Nucleic Acid BCTs over 5 days [16].

The Scientist's Toolkit:

• Blood Collection Tubes: Streck Nucleic Acid BCT (RUO, 5 mL or 10 mL) [14] [16].
• Plasma Processing: Centrifuge.
• RNA Extraction Kit: Maxwell RSC miRNA Plasma and Serum Kit (Promega) or miRNeasy Serum/Plasma Kit (Qiagen) [16].
• Analysis: qRT-PCR System with specific miRNA assays (e.g., miRCURY LNA miRNA PCR Assays).

Workflow:

• Collection & Storage: Collect blood into Nucleic Acid BCTs and store them at ambient temperature for 0, 1, 3, and 5 days.
• Plasma Isolation: At each time point, mix tubes and process plasma using a double-spin protocol (e.g., 1800 xg for 15 min, followed by 2800 xg for 15 min) [16].
• RNA Extraction: Extract total RNA (including miRNA) from 200 µL of plasma using an optimized kit like the Maxwell RSC miRNA Plasma and Serum Kit.
• cDNA Synthesis & qPCR: Reverse transcribe the RNA using a miRNA-specific RT kit. Perform quantitative PCR using SYBR Green and LNA-enhanced primers for specific miRNAs of interest (e.g., cancer-associated miRNAs).
• Data Analysis: Compare the Cycle threshold (Ct) values across time points. Stable Ct values from day 0 to day 5 indicate successful stabilization of miRNA.

Streck blood collection tubes provide a robust solution to the critical challenge of pre-analytical variation in liquid biopsy research. Their core chemical cross-linking mechanism effectively stabilizes nucleated blood cells, preventing lysis and preserving the native state of fragile analytes like cfDNA, cfRNA, and miRNAs. As demonstrated by both manufacturer claims and independent validation, this technology enables room-temperature stability for extended periods, which is indispensable for the logistical practicality of multi-center trials and clinical research. By integrating Streck tubes and the detailed protocols provided into their workflows, researchers and drug development professionals can significantly enhance the reliability and reproducibility of their ctDNA and liquid biopsy studies.

Cell-Free DNA Blood Collection Tubes (cfDNA BCTs) are specialized devices designed to maintain the integrity of biological samples from the moment of blood draw through transport and storage. By stabilizing nucleated blood cells, these tubes prevent the release of genomic DNA that would otherwise dilute or compromise the quality of circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs). This stabilization is critical for reliable downstream molecular analyses in liquid biopsy applications, including cancer diagnostics, non-invasive prenatal testing (NIPT), and drug development.

The table below summarizes the key stability specifications for leading commercial cfDNA BCTs, providing researchers with essential data for experimental planning.

Table 1: Key Stability Specifications for cfDNA and CTCs in Blood Collection Tubes

Manufacturer & Tube Name	cfDNA Stability	CTC Stability	Tube Material	Shelf Life
Streck Cell-Free DNA BCT [9] [19]	Up to 14 days at 6°C to 37°C	Up to 7 days at 15°C to 30°C	Glass	24 months
Roche Cell-Free DNA Collection Tube [10]	Up to 7 days at ambient temperatures (supported by data)	Information Not Specified	Plastic (PET)	18 months
Norgen cf-DNA/cf-RNA Preservative Tube [20]	Up to 30 days at room temperature; 8 days at 37°C	Up to 14 days at room temperature	Plastic (PET)	Information Not Specified

Experimental Protocols for Validation

Robust validation of cfDNA BCT performance is essential for generating reliable data. The following protocol, adapted from a 2023 peer-reviewed study, provides a detailed methodology for evaluating tube performance in an oncological context [6] [21].

Protocol: Evaluating cfDNA BCTs for Liquid Profiling in Oncology

Objective: To compare the performance of Streck cfDNA BCTs against standard K₂EDTA tubes for the stabilization of cfDNA and analysis of circulating tumor DNA (ctDNA) in blood samples from cancer patients [21].

Materials and Reagents:

• Blood samples from consented cancer patients (e.g., colorectal, pancreatic, non-small-cell lung cancer)
• Streck cfDNA BCTs and matched K₂EDTA tubes
• Centrifuge with swing-out rotor
• QIAamp Circulating Nucleic Acid Kit (Qiagen)
• LINE-1 qPCR assay (96 bp and 402 bp amplicons)
• Droplet digital PCR (ddPCR) assays for relevant mutations (e.g., KRAS, NRAS, EGFR)

Methodology:

• Blood Collection and Storage: Collect venous blood into both Streck cfDNA BCTs and K₂EDTA tubes. Invert tubes 10 times immediately after collection [21].
• Storage Conditions: Process K₂EDTA tubes within 2 hours and 6 hours of draw. Process Streck cfDNA BCTs after 2 hours and 3 days of storage at room temperature (as outlined in Figure 1)
• Plasma Processing:
  • Centrifuge tubes at 1,600 × g for 10 minutes at room temperature using a smooth braking profile.
  • Carefully transfer the plasma supernatant to a fresh tube without disturbing the buffy coat.
  • Perform a second centrifugation at 6,000 × g for 10 minutes.
  • Transfer the final plasma supernatant into cryotubes and store at -80°C [21].
• cfDNA Extraction: Extract cfDNA from 2 mL of plasma using the QIAamp Circulating Nucleic Acid Kit. Extend the proteinase K incubation time to 60 minutes for all samples to ensure comparability [21].
• Downstream Analysis:
  • Quantification and gDNA Contamination: Quantify cfDNA using a LINE-1 qPCR assay. Use a short amplicon (96 bp) to quantify total cfDNA and a long amplicon (402 bp) to assess genomic DNA contamination. A high ratio of long-to-short amplicons indicates significant white blood cell lysis and sample degradation [21].
  • Mutation Analysis: Perform mutation analysis using highly sensitive BEAMing ddPCR or similar technology to detect tumor-specific mutations in genes such as KRAS, NRAS, and EGFR [21].

Conclusion: This protocol allows for the direct comparison of sample stability between tube types, confirming that cfDNA yield, gDNA contamination levels, and mutant allele frequencies remain stable in cfDNA BCTs after prolonged storage [21].

Workflow and Stabilization Mechanism

The following diagram illustrates the experimental workflow and the core biological principle of cfDNA BCTs, which is the stabilization of white blood cells to prevent the release of genomic DNA.

Diagram 1: Experimental workflow and stabilization mechanism of cfDNA BCTs versus K₂EDTA tubes.

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful execution of liquid biopsy protocols requires specific reagents and materials. The table below details essential components for a typical workflow, as cited in the referenced studies.

Table 2: Essential Research Reagents and Materials for cfDNA Analysis

Item Name	Function/Description	Example Use in Protocol
Streck Cell-Free DNA BCT [9] [6]	Stabilizes cfDNA and CTCs by inhibiting nuclease activity and preventing white blood cell lysis.	Primary blood collection device for extended sample stability.
BD Vacutainer K₂EDTA Tubes [21] [22]	Standard blood collection tube with anticoagulant; requires rapid processing.	Control tube for comparing pre-analytical stability (process within 4-6 hours).
QIAamp Circulating Nucleic Acid Kit [21]	Silica-membrane based kit optimized for purifying short-fragment cfDNA from large-volume plasma samples.	Extraction of cfDNA from 2-4 mL of plasma.
LINE-1 qPCR Assay [21]	Quantitative PCR assay targeting repetitive LINE-1 elements to quantify total cfDNA (96 bp amplicon) and genomic DNA contamination (402 bp amplicon).	Assessment of cfDNA yield and sample quality.
BEAMing ddPCR [21]	Highly sensitive digital PCR technology (Beads, Emulsion, Amplification, and Magnetics) for detecting low-frequency mutations.	Detection and quantification of tumor-specific mutations (e.g., in KRAS, EGFR).
Roche Cell-Free DNA Collection Tube [10] [22]	Plastic (PET) blood collection tube with a proprietary formulation to prevent cell lysis and stabilize cfDNA.	Alternative stabilization tube for studies requiring a non-glass container.

Critical Considerations for Pre-Analytical Workflow

The integrity of cfDNA and CTC samples is profoundly affected by pre-analytical variables. Key considerations include:

• Transport Method: A 2025 study indicates that transport via Pneumatic Tube Systems (PTS) can subject samples to significant forces. While findings suggest PTS transport introduces only minor variations in cfDNA concentration that do not significantly impact ctDNA interpretation, the effect should be evaluated for each specific PTS line [22].
• Tube Material: Streck tubes are made of glass, which may require careful handling during transport, whereas Roche and Norgen offer plastic (PET) alternatives that reduce breakage risk [10] [22] [20].
• Harmonization of Protocols: The lack of harmonized pre-analytical standards across studies can lead to deviating performances in cfDNA applications. Adopting a consistent protocol for blood collection, storage time, centrifugation, and DNA extraction is crucial for ensuring reproducible and reliable results [21].

Implementing Streck Tubes in Your Liquid Biopsy Workflow

This Standard Operating Procedure (SOP) details the protocol for obtaining plasma suitable for circulating tumor DNA (ctDNA) analysis from whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (cfDNA BCT). The procedure is critical for liquid biopsy applications in oncology research, drug development, and clinical studies. Proper pre-analytical handling is essential for maintaining ctDNA stability and preventing genomic DNA contamination, which directly impacts the sensitivity and accuracy of downstream molecular analyses such as next-generation sequencing and digital PCR [21].

The core advantage of Streck cfDNA BCT tubes is their ability to stabilize blood samples, preventing white blood cell lysis and nuclease-mediated degradation of cell-free DNA. This allows for room temperature storage and eliminates the need for immediate processing after blood draw, which is a significant logistical advantage over conventional K₂EDTA tubes [9] [21]. This SOP ensures the standardization of sample handling, from venipuncture to plasma isolation, to ensure the integrity of analytes for reliable liquid biopsy testing.

Principle

Streck cfDNA BCTs contain a proprietary preservative reagent that acts through chemical cross-linking to stabilize nucleated blood cells [13]. This stabilization is crucial for pre-analytical workflow, as it:

• Inhibits white blood cell lysis, thereby limiting the release of contaminating genomic DNA that would dilute the mutant allele frequency of ctDNA [21] [8].
• Minimizes the degradation of existing cell-free DNA and circulating tumor cells (CTCs) by inhibiting nucleases [9].
• Enables cold chain-free transport, allowing samples to be stored and shipped at room temperature (6°C to 37°C) for up to 14 days for cfDNA analysis without significant loss of sample quality [9] [21].

Materials and Equipment

Research Reagent Solutions and Consumables

Table 1: Essential Materials for Blood Collection and Plasma Processing

Item	Function/Description
Streck Cell-Free DNA BCT (10 mL draw)	Blood collection tube containing preservative for stabilizing cfDNA and CTCs. For Research Use Only (RUO) or In Vitro Diagnostic (IVD) use, depending on region and application [9] [23].
Tourniquet	Standard phlebotomy tourniquet for venous access.
Alcohol swabs	For disinfecting the venipuncture site.
Sterile needles (e.g., 21G)	For venous blood draw.
Tube rack	For holding blood collection tubes upright.
Pipettes and sterile tips	For precise liquid handling.
15 mL conical centrifuge tubes	For containing plasma after initial processing.
Cryogenic vials	For long-term storage of plasma aliquots at -80°C.

Equipment

• Centrifuge with a swing-out rotor and temperature control (capable of 1600 × g and 6000 × g)
• Refrigerator (4°C) and freezer (-80°C)
• Personal protective equipment (PPE): lab coat, gloves, safety glasses

Procedure

Blood Collection and Handling

• Patient Identification & Labeling: Confirm patient identity. Label the Streck cfDNA BCT with the required patient and sample information.
• Venipuncture: Perform venous blood draw using standard phlebotomy techniques. Draw blood directly into a Streck cfDNA BCT.
• Tube Filling: Ensure the tube is filled to its nominal 10 mL volume to maintain the correct blood-to-preservative ratio [21].
• Mixing: Immediately after the draw, gently invert the tube 10 times to ensure thorough mixing of the blood with the preservative reagent [21].
• Storage & Transport: Store and transport blood samples upright at room temperature (15°C to 30°C). Do not freeze or refrigerate samples.

Plasma Isolation Protocol

The following workflow outlines the centrifugation procedure for plasma isolation. Adherence to specified time, temperature, and g-force parameters is critical for obtaining high-quality plasma.

Critical Steps and Notes:

• Time to Processing: Plasma can be isolated immediately or after a delay of up to 14 days at room temperature without significant genomic DNA contamination [9] [21]. For optimal cfDNA yield in oncological applications, processing within 3 days is recommended [21].
• Centrifugation Parameters: Using a swing-out rotor and a smooth braking profile is essential to prevent disturbing the buffy coat layer, which would contaminate the plasma with white blood cells.
• Plasma Transfer: During the first transfer, leave approximately 500 µL of plasma above the buffy coat. After the second spin, leave about 300 µL above the potential pellet to avoid cellular contamination [21].
• Aliquoting: Aliquot plasma into cryovials to avoid freeze-thaw cycles, which can fragment DNA and compromise sample integrity.

Quality Control and Performance Data

Assessment of Sample Quality

To ensure the isolated plasma is of high quality for ctDNA analysis, the following QC metrics should be considered:

• cfDNA Quantification: Use fluorometric analysis (e.g., Qubit) or quantitative PCR (qPCR) targeting short amplicons (e.g., 60-96 bp) to determine cfDNA concentration [13] [21].
• gDNA Contamination Assessment: Employ a qPCR assay that targets a long amplicon (>400 bp). A low ratio of long/short amplicon signal indicates minimal gDNA contamination [21]. Alternatively, capillary electrophoresis can be used to visualize the cfDNA fragment size profile, where a dominant peak at ~165 bp indicates good quality [13] [8].

Stability Data and Comparison to K₂EDTA Tubes

The table below summarizes key quantitative findings from recent studies on the performance of Streck cfDNA BCTs, providing an evidence-based rationale for this SOP.

Table 2: Comparative Pre-analytical Performance of Streck cfDNA BCTs

Evaluation Parameter	Streck cfDNA BCT Performance	Standard K₂EDTA Tube Performance	Reference & Study Details
cfDNA Stability (Time)	Stable for up to 14 days at 6°C-37°C [9]. No significant increase in cfDNA yield or gDNA contamination after 3 days at RT in patient samples [21].	Requires processing within 4-6 hours; delayed processing leads to significant gDNA contamination [21] [8].	Sysmex Inostics GmbH, 2023 (n=53 cancer patients) [21].
cfDNA Yield Over Time	-13.1% change after 7 days at RT compared to baseline (0h) [13].	+68.19x increase after 7 days at RT vs. baseline, indicating massive gDNA release [13].	Scientific Reports, 2025 (n=23 healthy individuals, 649 samples) [13].
Mutation Detection	Highly comparable mutational load and allele frequency detected in samples stored for up to 3 days vs. K₂EDTA processed immediately [21].	Reliable only if processed immediately; mutations can be obscured by wild-type gDNA background after lysis.	Sysmex Inostics GmbH, 2023; using BEAMing ddPCR for KRAS, NRAS, EGFR [21].
gDNA Contamination	Maintains low levels of gDNA contamination (low 402:96 bp LINE-1 ratio) after 3 days [21].	gDNA contamination increases significantly after 6 hours at RT [21].	Sysmex Inostics GmbH, 2023 [21].

Troubleshooting

Table 3: Common Issues and Corrective Actions

Problem	Potential Cause	Corrective Action
High gDNA contamination	Brake setting too high during centrifugation, disturbing the buffy coat.	Use a smooth braking profile during all centrifugation steps.
	Plasma transferred too close to the buffy coat layer.	Leave a 300-500 µL cushion of plasma above the buffy coat/pellet.
Low cfDNA yield	Incomplete mixing of blood with preservative.	Invert the tube 10 times immediately after blood draw.
	Plasma not transferred completely.	Ensure pipette tips are not blocked during transfer.
Hemolyzed sample	Difficult venipuncture.	Ensure a clean, efficient blood draw.

Safety Considerations

All human-derived samples must be handled as potentially infectious. Wear appropriate PPE. Dispose of all sharps and biohazardous waste according to institutional safety regulations.

The integrity of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in blood samples is paramount for the reliability of downstream molecular analyses, including PCR, droplet digital PCR (ddPCR), and Next Generation Sequencing (NGS). Streck blood collection tubes contain a preservative reagent that stabilizes blood samples by preventing the release of genomic DNA from white blood cells and minimizing the degradation of cfDNA/ctDNA [9]. This stabilization is crucial for accurate liquid biopsy testing, as it maintains the original profile of nucleic acids from the moment of blood draw, enabling room temperature transportation and storage without compromising sample quality [12] [9]. This application note details the compatibility of Streck tube-stabilized samples with advanced molecular applications, providing validated protocols and performance data for researchers and drug development professionals.

Streck Blood Collection Tube Portfolio and Specifications

Streck offers a range of blood collection tubes designed to stabilize different analytes critical for liquid biopsy research. The table below summarizes key products and their stabilization capabilities.

Table 1: Streck Stabilization Blood Collection Tubes for Liquid Biopsy Research

Product Name	Stabilized Analytes	Stability Duration	Key Benefits	Suitable Downstream Applications
Cell-Free DNA BCT [9]	Cell-free DNA, Circulating Tumor Cells (CTCs)	cfDNA: 14 days (6°C–37°C)CTCs: 7 days (15°C–30°C)	Prevents gDNA release, minimizes CTC degradation	PCR, ddPCR, NGS, CTC analysis
Nucleic Acid BCT [12]	Cell-free DNA, Cell-free RNA, Extracellular Vesicles	7 days at room temperature	Co-stabilization of cfDNA and cfRNA	NGS, RT-PCR, transcriptome sequencing
Protein Plus BCT [12]	Plasma Proteins	5 days at ambient temperature*	Maintains draw-time protein concentrations	Protein biomarker analysis

*These performance characteristics have not been evaluated by the U.S. Food & Drug Administration. All products listed are For Research Use Only. Not for use in diagnostic procedures [9].

Performance Comparison of Downstream Applications

Quantitative Data on Application Sensitivity

The choice of detection method significantly impacts the sensitivity of ctDNA analysis. The following table compiles comparative performance data from studies that utilized Streck tubes for sample collection.

Table 2: Performance Comparison of ddPCR vs. NGS for ctDNA Detection from Streck-Stabilized Blood

Study Context	Detection Method	Reported Sensitivity	Key Findings
HPV16-Oropharyngeal Cancer [24]	NGS	70% (in plasma)	NGS demonstrated superior sensitivity for HPV16 detection in plasma compared to ddPCR and qPCR.
	ddPCR	70% (in plasma)	ddPCR showed equivalent sensitivity to NGS in plasma but poor performance in oral rinse (8.3%).
	qPCR	20.6% (in plasma)	qPCR sensitivity was significantly lower than both NGS and ddPCR.
Localized Rectal Cancer [25]	ddPCR	58.5% (baseline plasma)	ddPCR detected ctDNA in a higher proportion of pre-therapy plasma samples compared to NGS.
	NGS Panel	36.6% (baseline plasma)	The NGS panel was less sensitive than ddPCR for detecting pre-therapy ctDNA in this cohort.

Analysis of Method Selection

The data indicates that the optimal detection method depends on the specific research question and sample type:

• NGS excels in discovery applications and multiplexed analysis, as it can comprehensively profile multiple genetic alterations without prior knowledge of the specific mutations [26]. It is particularly effective for detecting viral DNA, as demonstrated in the oropharyngeal cancer study [24].
• ddPCR is ideal for high-sensitivity tracking of known mutations. It offers absolute quantification, low limits of detection (as low as 0.01% Variant Allele Frequency), and is more cost-effective for analyzing a small number of targets [25] [26]. Its strength is confirmed in monitoring specific mutations in rectal cancer [25].
• qPCR, while useful, generally provides lower sensitivity compared to ddPCR and NGS, making it less suitable for detecting very low levels of ctDNA [24].

Experimental Protocols

Standardized Protocol for Blood Collection and Processing with Streck Tubes

The following workflow diagram outlines the key steps from blood collection to analysis.

Title: Workflow from Blood Collection to Downstream Analysis

Detailed Procedure:

• Blood Collection: Draw venous blood into Streck Cell-Free DNA BCT tubes. Invert the tube 8-10 times immediately after collection to ensure proper mixing with the preservative [25] [9].
• Storage & Transport: Tubes can be stored and shipped at room temperature (6°C–37°C). Plasma separation should be performed within 14 days of blood collection for optimal cfDNA preservation [9].
• Plasma Separation:
  • Centrifuge tubes at a minimum of 1600 RCF for 20 minutes at room temperature to separate plasma from cellular components.
  • Carefully transfer the supernatant (plasma) to a new tube without disturbing the buffy coat.
  • Perform a second centrifugation step of the transferred plasma at 16,000 RCF for 10 minutes to remove any residual cells [25].
• cfDNA Extraction: Extract cfDNA from the clarified plasma using a dedicated kit, such as the QIAamp Circulating Nucleic Acid Kit, following the manufacturer's instructions [24]. Elute the cfDNA in a low-EDTA or EDTA-free buffer.
• Quality Control (QC): Quantify and qualify the extracted cfDNA. Fluorometry (e.g., Qubit) is preferred for accurate concentration measurement of double-stranded DNA. For functional QC of NGS libraries, droplet digital PCR (ddPCR) provides absolute quantification of adapter-ligated fragments, which is superior to spectrophotometry or electrophoresis for predicting sequencing performance [27] [26].

Protocol for NGS Library Quantification using ddPCR

Accurate quantification of NGS libraries is critical for achieving optimal sequencing cluster density. ddPCR provides absolute quantification of functional, adapter-ligated library fragments, avoiding the inaccuracies of mass-based methods [26].

Table 3: Comparison of NGS Library Quantification Methods

Method	Instrument Examples	Quantification Modality	Quantification of Functional Libraries?
Spectrophotometry	NanoDrop	Mass / Absolute	Not possible [26]
Fluorometry	Qubit, PicoGreen	Mass / Relative	Not possible [26]
qPCR-based	QIAquant	Molecules / Relative	Possible [26]
dPCR-based	QIAcuity, QX200	Molecules / Absolute	Yes [26]

Procedure:

• Dilute Library: Dilute the prepared NGS library to an expected concentration within the linear range of the ddPCR system (typically around 1-100 copies/µL).
• Prepare Reaction Mix: Prepare the ddPCR reaction mix containing supermix, primers, and a fluorescent probe (e.g., FAM-labeled) specific to the adapter sequence (e.g., P5/P7) of your NGS library.
• Partition Generation: Generate droplets using a droplet generator (e.g., Bio-Rad QX200).
• PCR Amplification: Perform endpoint PCR amplification on the emulsified reactions.
• Droplet Reading and Analysis: Read the plate on a droplet reader and analyze using the instrument's software (e.g., QuantaSoft). The concentration of functional library molecules (in copies/µL) is calculated directly using Poisson statistics [26].

Decision Framework for Application Selection

The following diagram illustrates the decision-making process for selecting the appropriate downstream analytical method.

Title: Decision Framework for Selecting Detection Method

Research Reagent Solutions

A successful experiment relies on a suite of reliable reagents and tools. The following table lists essential materials used in the featured studies and their specific functions.

Table 4: Essential Research Reagents and Kits for ctDNA Analysis

Item Name	Function / Application	Example Use in Context
Streck Cell-Free DNA BCT [25] [9]	Stabilizes cfDNA and CTCs in whole blood for up to 14 days at room temperature.	Used for pre-therapy blood collection in rectal cancer ctDNA studies [25].
QIAamp Circulating Nucleic Acid Kit [24]	Extracts high-quality cfDNA from plasma samples.	Used for DNA extraction from plasma and oral rinse in HPV-OPC research [24].
ddPCR System (e.g., Bio-Rad QX200) [24] [25]	Provides absolute quantification of target DNA sequences with high sensitivity.	Used for detecting HPV16 DNA [24] and rectal cancer ctDNA [25] in plasma.
NGS Library Prep Kits (e.g., Illumina TruSeq, NEBNext) [27]	Prepares cfDNA libraries for sequencing by fragmenting, end-repairing, and adding adapters.	Various kits were compared for efficiency and bias in library preparation [27].
Ion AmpliSeq Cancer Hotspot Panel v2 [25]	An NGS panel for targeted sequencing of hotspot regions in 50 cancer-related genes.	Used to identify tumor-specific mutations in rectal cancer samples for informed ddPCR assay design [25].

The analysis of circulating tumor DNA (ctDNA) has emerged as a transformative approach in oncology, enabling non-invasive assessment of tumor genomics for diagnostic, prognostic, and treatment monitoring applications. The pre-analytical phase—encompassing sample collection, stabilization, transport, and processing—represents a critical determinant of data quality in liquid biopsy workflows. Without proper stabilization, white blood cells begin to lyse during storage and transport, releasing abundant genomic DNA that dilutes the already scarce ctDNA fragments and jeopardizes the detection of low-frequency mutations. Streck Cell-Free DNA Blood Collection Tubes (cfDNA BCTs) contain a proprietary preservative that stabilizes nucleated blood cells and inhibits nuclease activity, thereby maintaining the integrity of the cell-free DNA population and minimizing contamination by genomic DNA. This application note details standardized protocols and presents performance data validating Streck cfDNA BCTs for diverse oncological applications, from metastatic monitoring to early-stage trial design.

Performance Validation: Quantitative Stability Data Across Cancer Types

Extensive validation studies have demonstrated that Streck cfDNA BCTs maintain sample integrity across diverse storage conditions and cancer types, ensuring reliable analysis of ctDNA.

Table 1: Stability Performance of Streck cfDNA BCTs in Oncology Studies

Cancer Type	Sample Size	Storage Condition	Key Analytical Metrics	Performance Outcome	Citation
Colorectal, Pancreatic, NSCLC	53 patients	3 days at RT (cfDNA BCT) vs. 6 hours (K2EDTA)	cfDNA yield, gDNA contamination, mutation detection (BEAMing ddPCR)	Comparable cfDNA yield and mutant allele frequencies across tube types and storage durations; reliable mutation detection post-storage.	[6]
Healthy Donors & Colorectal Cancer	Not Specified	0, 48, 168 hours at RT	cfDNA yield (qPCR), cellular DNA contamination (qPCR, capillary electrophoresis)	Stable cfDNA yield in Streck tubes over 7 days; minimal cellular DNA release.	[13]
Diffuse Large B-Cell Lymphoma (DLBCL)	8 healthy donors	0, 1, 4, 24 hours at RT	cfDNA yield (Qubit), gDNA contamination (Bioanalyzer)	High cfDNA yield and stable fragmentation profiles with recommended double-centrifugation protocol.	[28]
Triple-Negative & Luminal B Breast Cancer	40 patients	Plasma isolated within 96 hours	ctDNA detection (Oncomine panel, mFAST-SeqS, sWGS, MeD-Seq)	Successful multi-assay ctDNA detection from plasma isolated from Streck tubes, enabling tumor-agnostic profiling.	[29]
General Oncology (Review)	N/A	Up to 14 days at 6°C-37°C	Sample stability for ctDNA analysis	Eliminates cold chain requirement, facilitates centralized testing and clinical trial logistics.	[9]

The data consolidated in Table 1 underscore the robustness of Streck cfDNA BCTs. A 2023 multi-cancer study confirmed that blood samples from patients with colorectal, pancreatic, and non-small cell lung cancer (NSCLC) stored in Streck tubes for three days at room temperature yielded cfDNA and mutation profiles highly comparable to those from K2EDTA tubes processed within the narrow 6-hour window [6]. This stability is paramount for detecting low-frequency mutations, as the preservative effectively minimizes the release of wild-type genomic DNA from white blood cells, thereby preventing the dilution of the mutant allele frequency [2].

Recent technological advances have expanded the application of stabilized samples to novel, tumor-agnostic detection methods. A 2025 breast cancer study successfully utilized plasma from Streck tubes for four different analytical approaches, including mutation hotspot panels, copy number alteration analysis, and genome-wide methylation profiling [29]. This demonstrates the tubes' compatibility with a broad spectrum of downstream applications critical for modern clinical trials and precision oncology.

Application-Specific Protocols

Protocol for Metastatic Disease Monitoring and Therapy Selection

Application Note: This protocol is optimized for reliable detection of somatic mutations in patients with advanced solid tumors (e.g., NSCLC, CRC, Breast Cancer) to guide initial therapy or monitor the emergence of resistance mutations.

Materials & Reagents:

• Streck Cell-Free DNA BCT (10 mL) [9]
• QIAamp Circulating Nucleic Acid Kit (Qiagen) [6] [28]
• Equipment for centrifugation with swing-out rotor
• BEAMing ddPCR or NGS reagents for mutation detection (e.g., Oncomine Panels) [6] [29]

Workflow:

• Blood Collection and Storage: Collect venous blood into Streck cfDNA BCTs. Invert tubes 10 times immediately after draw [6]. Samples can be stored or shipped at room temperature (6°C to 37°C) for up to 3 days for reliable ctDNA analysis in oncology [6] [9].
• Plasma Processing (Double Centrifugation):
  • Centrifuge blood tubes at 1,600 × g for 10 minutes at room temperature using a swing-out rotor and a smooth braking profile [6] [28].
  • Carefully transfer the supernatant (plasma) to a fresh tube without disturbing the buffy coat.
  • Perform a second centrifugation of the plasma at 16,000 × g for 10 minutes at room temperature [28] or at 6,000 × g for 10 minutes [6] to remove any remaining cellular debris.
  • Aliquot and store cleared plasma at -80°C if not extracting immediately.
• cfDNA Extraction: Extract cfDNA from 2-4 mL of plasma using the QIAamp Circulating Nucleic Acid Kit. For samples in Streck tubes, extend the proteinase K digestion step to 60 minutes at 60°C to ensure optimal yield [6]. Elute in a volume suitable for downstream analysis (e.g., 50-140 µL).
• Mutation Detection: Analyze eluted cfDNA using highly sensitive methods such as BEAMing ddPCR [6] [2] or targeted NGS panels (e.g., Oncomine Breast cfDNA panel) [29]. These methods are validated for use with samples stabilized in Streck tubes and are capable of detecting mutant allele frequencies below 1%.

Protocol for Early-Stage Trial Design and MRD Detection

Application Note: This protocol is designed for high-sensitivity applications in early-stage cancer, including minimal residual disease (MRD) monitoring and early detection, where ctDNA fractions can be exceptionally low (<< 0.1%).

Materials & Reagents:

• Streck Cell-Free DNA BCT (10 mL) [9]
• QIAamp Circulating Nucleic Acid Kit (Qiagen) or automated systems (e.g., QIAsymphony SP) [13]
• Reagents for multi-modal analysis (e.g., MeD-Seq for methylation, sWGS for fragmentomics) [30] [29]

Workflow:

• Blood Collection and Storage: Adhere to the same collection procedure as in Protocol 3.1. For studies involving batch analysis from multiple clinical sites, the 14-day stability claim of Streck tubes provides critical logistical flexibility for shipping to a central laboratory [9].
• Plasma Processing: Follow the identical double-centrifugation protocol described in Section 3.1, Step 2. Consistency in plasma preparation is crucial for the integrity of fragmentomic and epigenomic analyses.
• cfDNA Extraction: Use automated, high-recovery extraction systems like the QIAsymphony SP to maximize yield and ensure consistency across large sample sets [13].
• Multi-Modal ctDNA Analysis: Employ tumor-agnostic, genome-wide techniques to overcome the challenge of low tumor fraction in early-stage disease:
  • Methylation Profiling: Use assays like MeD-Seq to detect cancer-associated hypermethylation patterns. This method has demonstrated higher sensitivity than SNV- or CNV-based approaches in early breast cancer [29].
  • Fragmentomics: Utilize shallow Whole Genome Sequencing (sWGS) to analyze cfDNA fragmentation patterns (e.g., via the DELFI method) to distinguish cancer-derived from normal cfDNA [30] [29].
  • Copy Number Alteration (CNA) Detection: Apply the mFAST-SeqS method to screen for genome-wide aneuploidy as a surrogate for ctDNA presence [29].

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 2: Key Materials for ctDNA Pre-Analytical Workflows

Item Name	Specific Function	Key Features & Research Use
Streck cfDNA BCT [9]	Stabilizes cfDNA and prevents gDNA release from white blood cells.	- 14-day cfDNA stability at 6°C-37°C.- Enables room-temperature transport.- For Research Use Only.
QIAamp Circulating Nucleic Acid Kit [6] [28]	Silica-membrane-based purification of high-quality cfDNA from plasma.	- High yield and purity.- Compatible with plasma from Streck BCTs (requires extended proteinase K digestion).
QIAsymphony SP [13]	Automated, magnetic bead-based nucleic acid extraction system.	- High-throughput, reproducible cfDNA extraction.- Compatible with plasma from Streck and K2EDTA tubes.
BEAMing ddPCR [6] [2]	Ultra-sensitive mutation detection for single or few targets.	- Capable of detecting mutant allele frequencies < 0.1%.- Validated for use with cfDNA from Streck tubes.
Oncomine Breast cfDNA Panel [29]	Targeted NGS for hotspot mutations in breast cancer genes.	- Analyzes 150+ hotspots in 10 genes.- Used in tumor-agnostic detection from stabilized plasma.
MeD-Seq [29]	Genome-wide methylation profiling from cfDNA.	- Tumor-agnostic detection method.- Shows high sensitivity in early breast cancer.

Streck cfDNA BCTs provide a robust and reliable solution for standardizing the pre-analytical phase of liquid biopsy workflows across the cancer care continuum. The validated protocols and performance data presented herein provide researchers and drug development professionals with the necessary tools to implement these tubes confidently in studies ranging from metastatic monitoring to the demanding arena of early-stage trial design and MRD detection. By ensuring sample integrity from the point of collection to the final analysis, Streck tubes facilitate the generation of high-quality, reproducible genomic data that is essential for advancing precision oncology.

Integration with Automated cfDNA Extraction Platforms

The analysis of circulating tumor DNA (ctDNA) from liquid biopsies has emerged as a powerful, non-invasive tool for cancer detection, tumor profiling, and therapeutic monitoring [31]. A core challenge in realizing the full potential of ctDNA is its low and variable abundance in plasma, its high degree of fragmentation, and its susceptibility to pre-analytical variability [31]. The period between blood collection and plasma processing is particularly critical. If not stabilized, nucleated blood cells can lyse, releasing large quantities of wild-type genomic DNA that can overwhelm the rare ctDNA fragments, effectively "dumping a few hundred more bales of hay on top of the needle in the haystack" [32]. Streck Cell-Free DNA Blood Collection Tubes (BCTs) are designed to address this exact problem by stabilizing blood samples, preventing the release of genomic DNA from white blood cells, and enabling room temperature transport for up to 14 days [12] [9]. This application note details the protocols and data for the seamless integration of Streck BCT-collected samples with automated, high-throughput cfDNA extraction platforms, a combination essential for achieving standardized, robust, and efficient workflows in clinical and research settings.

Stabilization Mechanism and Workflow Integration

Streck Cell-Free DNA BCTs contain a preservative reagent that limits the release of genomic DNA from white blood cells and minimizes the degradation of circulating tumor cells [9]. This stabilization is the foundational step that makes delayed processing and automation feasible. The following diagram illustrates the integrated workflow from blood draw to downstream analysis, highlighting how Streck BCTs fit into the automated ecosystem.

Quantitative Comparison of Automated cfDNA Extraction Platforms

The choice of an automated extraction system significantly impacts the yield, quality, and suitability of the isolated cfDNA for sensitive downstream applications like next-generation sequencing (NGS). The following table summarizes key performance characteristics of two widely used magnetic bead-based automated systems, as validated with plasma from Streck BCTs.

Table 1: Evaluation of Automated cfDNA Extraction Platforms with Streck BCT Samples

Extraction Platform	Chemistry	Input Volume	Key Performance Characteristics	Best Suited For
EZ2 Connect (QIAGEN) [33]	Magnetic Bead	1-2 mL	• Significantly higher cfDNA yield• Higher proportion of short DNA fragments• Higher mitochondrial DNA yield• Lower DNA integrity (lower long/short fragment ratio)	Applications requiring maximum sensitivity and yield, such as low-VAF variant detection or mitochondrial DNA analysis.
Maxwell RSC (Promega) [33]	Magnetic Bead	0.4-1 mL	• Lower cfDNA yield compared to EZ2• Lower proportion of short fragments• Very low mitochondrial DNA co-isolation• Higher DNA integrity	Applications where minimal gDNA contamination is critical, potentially offering a "cleaner" background for mutation detection.
QIAsymphony (QIAGEN) [34]	Silica Membrane / Bead-Based	1-4 mL	• Lower recovery rates and cfDNA quantity compared to manual QIAamp CNA• High reproducibility• No gDNA contamination	High-throughput labs where full automation and reproducibility are prioritized over maximum yield.

Detailed Experimental Protocols

Protocol: Integrated Workflow from Streck BCT to Automated cfDNA Extraction

This protocol is adapted from studies that successfully utilized Streck BCTs for automated cfDNA extraction [31] [33].

Principle: To isolate high-quality, amplifiable cfDNA from blood collected in Streck Cell-Free DNA BCTs using an automated, magnetic bead-based platform for downstream liquid biopsy applications.

Research Reagent Solutions & Materials:

• Blood Collection Tube: Streck Cell-Free DNA BCT (10 mL) [12] [9].
• Automated Extraction System: EZ2 Connect Instrument (QIAGEN) or Maxwell RSC Instrument (Promega).
• Corresponding Kits: EZ1&2 ccfDNA Field Test Kit (QIAGEN) or Maxwell RSC ccfDNA Plasma Kit (Promega).
• Plasma Preparation: Polypropylene centrifuge tubes, pipettes, phosphate-buffered saline (PBS) if required.
• Quality Control (QC): Agilent TapeStation with High Sensitivity D1000 ScreenTape, Droplet Digital PCR (ddPCR) or quantitative PCR (qPCR) system [31] [32].

Procedure:

• Blood Collection and Storage: Collect blood via venipuncture directly into a Streck Cell-Free DNA BCT. Invert the tube 8-10 times immediately after collection to mix the blood with the preservative. Samples can be stored and transported at room temperature (6°C to 37°C) for up to 14 days prior to plasma processing [9].
• Plasma Separation (Double Centrifugation):
  • First Centrifugation: Centrifuge the BCTs at 1600 × g for 10 minutes at room temperature to separate plasma from blood cells [33].
  • Plasma Transfer: Carefully transfer the supernatant (plasma) to a new polypropylene tube using a pipette, without disturbing the buffy coat.
  • Second Centrifugation: Centrifuge the transferred plasma at 16,000 × g for 10 minutes to remove any remaining cellular debris [33].
  • Final Plasma Transfer: Transfer the clarified plasma into a fresh tube. Plasma can be stored at ≤ -80°C or proceed directly to extraction.
• Automated cfDNA Extraction:
  • Follow the manufacturer's instructions for the chosen automated system and kit.
  • For the EZ2 Connect with the EZ1&2 ccfDNA field test kit, use 1 mL of plasma as input. If the system requires a 2 mL minimum volume, add 1 mL of PBS [33].
  • For the Maxwell RSC with the Maxwell RSC ccfDNA Plasma Kit, use 1 mL of plasma as input [33].
  • Initiate the automated protocol, which typically includes steps for lysis, binding of cfDNA to magnetic beads/particles, washing, and elution in a small volume (e.g., 50-100 µL).
• Post-Extraction Quality Control:
  • Quantification: Use dye-based fluorescence assays (e.g., Qubit) for a rough estimate. For accurate quantification of amplifiable cfDNA, use qPCR or ddPCR, as fluorescence dyes can overestimate usable nucleic acids [32].
  • Fragment Size Analysis: Assess cfDNA quality and gDNA contamination using the Agilent TapeStation System. A clean cfDNA profile should show a dominant peak at ~167 bp (mononucleosomal). Ratios of 75:300 bp concentrations (e.g., from the ProNex DNA QC Assay) >10 indicate extremely clean cfDNA, while ratios close to 1 suggest gDNA contamination [32].

Protocol: Validation of Sample Stability in Streck BCTs

Principle: To confirm the stability of cfDNA and ctDNA in Streck BCTs over time at room temperature, ensuring integrity for delayed processing in automated workflows.

Experimental Setup:

• Collect blood from healthy donors and cancer patients into Streck BCTs and standard K₃EDTA tubes [35].
• Store samples at room temperature for various time points (e.g., 2h, 6h, 24h, 48h, 7 days, 14 days).
• At each time point, process the samples using the double centrifugation protocol described in 4.1.
• Extract cfDNA using a validated automated method.
• Analyze the extracted cfDNA using the following methods:

Table 2: Analytical Methods for Stability Validation

Analysis Method	Parameter Measured	Expected Outcome with Streck BCT
Droplet Digital PCR (ddPCR) [35]	Abundance of specific ctDNA mutations and wild-type DNA	Stable mutant allele frequency and wild-type DNA levels for up to 14 days.
Fragment Analysis (TapeStation) [31]	Fragment size distribution and gDNA contamination	Maintained mononucleosomal peak (~167 bp); minimal high molecular weight gDNA.
Next-Generation Sequencing (NGS) [31]	Variant detection accuracy and background noise	Strong concordance with expected variants; no increase in false positives over time.

The following workflow outlines the key steps in this stability validation experiment:

The Scientist's Toolkit: Essential Materials for Integrated Workflows

Table 3: Key Research Reagent Solutions for Automated cfDNA Workflows with Streck BCTs

Item	Function/Role	Example Products / Notes
Streck Cell-Free DNA BCT [9]	Stabilizes cell-free DNA and prevents white blood cell lysis for up to 14 days at 6-37°C, enabling room-temperature transport and batch processing.	Streck Cell-Free DNA BCT (RUO or CE-IVD).
Automated Nucleic Acid Extractor	Provides a high-throughput, reproducible platform for cfDNA isolation using magnetic bead chemistry, minimizing hands-on time and variability.	QIAGEN EZ2 Connect, Promega Maxwell RSC, Thermo Fisher KingFisher.
Magnetic Bead-Based cfDNA Kits	Designed for optimal binding and elution of short-fragment cfDNA from large-volume plasma samples on automated systems.	EZ1&2 ccfDNA Field Test Kit (QIAGEN), Maxwell RSC ccfDNA Plasma Kit (Promega).
Droplet Digital PCR (ddPCR)	Provides absolute quantification of specific mutations and wild-type DNA with high sensitivity; crucial for assessing extraction efficiency and ctDNA stability.	Bio-Rad QX200 System; used in stability studies [35].
Automated Electrophoresis System	Provides semi-quantitative analysis of cfDNA fragment size distribution and detects high molecular weight gDNA contamination.	Agilent TapeStation System with High Sensitivity D1000 reagents [31] [32].
cfDNA Reference Standards	Commercially available synthetic cfDNA with known mutations and fragment sizes, used for spike-in experiments to validate extraction recovery and workflow performance.	nRichDx cfDNA Standard, Seraseq ctDNA Reference Material, AcroMetrix ctDNA Controls [31].

The integration of Streck Cell-Free DNA BCTs with automated cfDNA extraction platforms creates a powerful, standardized workflow that effectively mitigates the critical pre-analytical variables in liquid biopsy. This combination ensures the stabilization of the sample from the moment of blood draw and leverages the reproducibility, efficiency, and high-throughput capabilities of automation. The data and protocols outlined in this application note provide researchers and drug development professionals with a validated framework to implement this integrated approach, thereby enhancing the reliability of cfDNA analysis for cancer detection, therapeutic monitoring, and the development of novel biomarkers.

Maximizing Data Quality: A Troubleshooting Guide for Pre-analytical Variables

The integrity of circulating tumor DNA (ctDNA) in liquid biopsy analysis is critically dependent on pre-analytical conditions. The time and temperature between blood collection and plasma processing are key variables that can significantly impact the accuracy of downstream molecular assays. Streck Cell-Free DNA Blood Collection Tubes (cfDNA BCTs) are specifically designed to stabilize blood samples, preventing the release of genomic DNA from white blood cells and protecting ctDNA from nuclease-mediated degradation. This document provides detailed application notes and protocols for the optimal storage and handling of blood samples collected in Streck tubes for ctDNA stability research, supporting reliable results in drug development and clinical studies.

Quantitative Stability Data

The following tables summarize key stability data for Streck cfDNA BCTs under various time and temperature conditions, providing a reference for experimental planning.

Table 1: Stability of Cell-Free DNA and Circulating Tumor Cells in Streck cfDNA BCTs

Analyte	Stability Duration	Temperature Range	Key Findings
Cell-Free DNA (cfDNA)	Up to 14 days [9]	6°C to 37°C [9]	Maintains cfDNA population and concentration; prevents gDNA release.
Circulating Tumor Cells (CTCs)	Up to 7 days [9]	15°C to 30°C [9]	Minimizes CTC degradation.
Circulating Tumor DNA (ctDNA)	Up to 3-7 days [35] [36] [21]	Room Temperature [35] [21]	Stable ctDNA levels and mutational load in oncology patient samples.

Table 2: Comparative Performance of Blood Collection Tube Types

Tube Type	Maximum Recommended Hold Time at RT	Key Stability Characteristics
Streck cfDNA BCT	Up to 14 days for cfDNA [9]	Superior long-term stability; prevents leukocyte lysis and gDNA contamination [35] [21].
K₂EDTA	≤ 6 hours [21]	Significant gDNA release and potential ctDNA decline observed after 48 hours [35].
Roche cfDNA Tube	< 7 days [36]	Suitable for room temperature storage, but duration is less than Streck tubes [36].

Experimental Protocols for Stability Validation

Protocol: Evaluating cfDNA Stability in Streck cfDNA BCTs Over Time

This protocol is adapted from studies comparing Streck tubes against other collection systems and validates stability under extended storage [36] [21].

• Blood Collection: Draw venous blood from patients or healthy volunteers into 10 mL Streck cfDNA BCTs using standard phlebotomy. Invert the tubes 10 times immediately after collection to ensure mixing with the preservative [21].
• Sample Storage: Store the filled tubes at room temperature (approx. 20-25°C). Do not refrigerate or freeze.
• Time-Point Processing: Process subsets of tubes at predetermined time points (e.g., 0, 2, 4, 7, 10, and 14 days) [36].
• Plasma Separation:
  • Centrifuge tubes at 1600 × g for 10 minutes at room temperature using a swing-out rotor. Use a smooth braking profile to avoid disturbing the buffy coat.
  • Carefully transfer the supernatant (plasma) to a fresh 15 mL tube without disrupting the buffy coat layer.
  • Perform a second centrifugation of the plasma at 6000 × g for 10 minutes at room temperature.
  • Transfer the clarified plasma into cryotubes and store at -80°C until DNA extraction [21].
• cfDNA Extraction: Extract cfDNA from 2 mL of plasma using a dedicated circulating nucleic acid kit (e.g., QIAamp Circulating Nucleic Acid Kit, Qiagen). For blood collected in Streck tubes, extend the proteinase K digestion step to 60 minutes at 60°C [21].
• Downstream Analysis:
  • Quantification: Measure total cfDNA yield using a fluorometer (e.g., Qubit Fluorometer) or quantitative PCR (qPCR) targeting short genomic amplicons (e.g., LINE-1, 96 bp) [36] [21].
  • gDNA Contamination Assessment: Use capillary electrophoresis (e.g., Agilent Bioanalyzer) or a qPCR assay for a long amplicon (e.g., LINE-1, 402 bp) to assess high molecular weight genomic DNA contamination. A low ratio of long/short amplicon concentration indicates minimal gDNA contamination and high sample quality [21].
  • Mutational Analysis: For oncology applications, use highly sensitive methods like BEAMing digital PCR or droplet digital PCR (ddPCR) to quantify mutant allele frequencies of specific genes (e.g., KRAS, NRAS, EGFR) across different time points [35] [21].

Protocol: Comparative Stability Against K₂EDTA Tubes

This protocol is designed to demonstrate the advantage of Streck tubes over standard K₂EDTA tubes.

• Blood Collection: Collect paired blood samples from the same donor into both Streck cfDNA BCTs and K₂EDTA tubes.
• Storage Conditions:
  • Process K₂EDTA tubes within 2 hours of draw (baseline) and after 6 hours of storage at room temperature.
  • Process Streck cfDNA BCTs after 2 hours and after 3 days (or longer) of storage at room temperature [21].
• Plasma Processing and Analysis: Follow the same steps for plasma separation, cfDNA extraction, and downstream analysis as described in Section 3.1. Compare the cfDNA yield, gDNA contamination levels, and mutant allele frequencies between tube types and across time points.

Workflow and Stability Diagrams

The following diagram illustrates the key steps and decision points in the sample handling workflow.

Research Reagent Solutions

Table 3: Essential Materials and Reagents for ctDNA Stability Research

Item	Function / Application	Example Product / Specification
Blood Collection Tube	Stabilizes cfDNA and CTCs; prevents gDNA release and nuclease degradation.	Streck Cell-Free DNA BCT (RUO or CE-IVD) [9] [23].
Plasma Preparation Tubes	For sequential centrifugation to obtain cell-free plasma.	15 mL conical tubes; cryotubes for storage.
cfDNA Extraction Kit	Isolates low-concentration cfDNA from plasma.	QIAamp Circulating Nucleic Acid Kit (Qiagen) [21].
DNA Quantification	Accurately measures low DNA concentrations and assesses fragment size.	Fluorometry (Qubit); Capillary Electrophoresis (Bioanalyzer); qPCR [36] [21].
Mutation Detection Platform	Sensitively detects and quantifies rare mutant alleles in a wild-type background.	Droplet Digital PCR (ddPCR; Bio-Rad QX200); BEAMing PCR [35] [21].

Within liquid biopsy workflows, the stability of circulating tumor DNA (ctDNA) is paramount for accurate molecular analysis. A significant pre-analytical challenge is the prevention of genomic DNA (gDNA) contamination, which can arise from the lysis of blood cells after blood collection. This contamination can dilute the already low-abundance ctDNA, compromising the sensitivity and specificity of downstream assays such as next-generation sequencing (NGS) [11] [37]. The use of specialized blood collection tubes (BCTs), such as the Streck Cell-Free DNA BCT, is a critical first step in a robust plasma processing protocol designed to maintain the integrity of the original cell-free DNA (cfDNA) population and minimize the release of cellular gDNA [9] [23]. This application note provides detailed protocols for plasma processing, framed within a broader thesis on utilizing Streck tubes for ctDNA stability research, to ensure the reliable detection of tumor-derived genetic variants.

The Critical Role of Blood Collection Tubes in gDNA Stabilization

Streck Cell-Free DNA BCTs are designed to stabilize blood samples by preserving nucleated blood cells, thereby limiting the release of genomic DNA that can occur during sample handling, shipping, and storage [9] [23]. The tube contains a preservative reagent that maintains the in vivo cell-free DNA profile for up to 14 days at temperatures ranging from 6°C to 37°C [9]. This stabilization is crucial for preventing pre-analytical variations that can confound ctDNA analysis.

The benefits of using these specialized tubes are multifaceted. They eliminate the need for immediate plasma isolation, which is typically required when using conventional ethylenediaminetetraacetic acid (EDTA) tubes [9] [11]. This allows for cold chain-free transportation of samples at ambient temperatures, facilitating centralized testing and multi-site clinical trials [9]. For researchers and drug development professionals, this translates to greater flexibility in study logistics and reduced risk of sample degradation. The table below summarizes a comparative analysis of blood collection tubes based on recent research.

Table 1: Comparison of Blood Collection Tube Performance for Liquid Biopsy

Tube Type	Stabilization Mechanism	Recommended Processing Timeline	Key Advantages	Considerations for gDNA Contamination
Streck Cell-Free DNA BCT	Chemical preservative stabilizes nucleated cells [9].	Up to 14 days at 6-37°C for cfDNA [9].	Room temperature transport; reduces pre-analytical variation [9] [1].	Actively inhibits leukocyte lysis, minimizing gDNA release [9] [23].
Conventional EDTA	Anticoagulant only; no cellular stabilization [11].	Within 2-6 hours at 4°C [11].	Low cost; widely available.	High risk of gDNA release from cells with delayed processing [11].
PAXgene Blood ccfDNA Tube	Chemical preservative.	Up to 7 days at room temperature [11].	Room temperature stability.	Stabilizes blood cells to prevent gDNA release.
Citrate Tubes	Anticoagulant.	Varies; often requires rapid processing.	Reduces hemolysis and platelet-derived EVs for proteomic studies [38].	Not specifically designed for cfDNA stabilization.

Impact of gDNA Contamination on Downstream Analysis

The intrusion of high molecular weight gDNA into plasma cfDNA samples directly compromises data quality. A 2025 study investigating the impact of long-term plasma storage demonstrated that gDNA contamination independently contributes to reduced success in sequencing library preparation and significantly compromises the quality of cfDNA epigenetic analyses, such as 5-hydroxymethylcytosine (5hmC) sequencing [37]. Specifically, samples with gDNA contamination exhibited significantly reduced uniquely mapped reads (UMRs), a key metric for sequencing efficiency and data quality [37]. This degradation of data can obscure true positive signals in ctDNA analysis, leading to false negatives or inaccurate variant allele frequency quantification, ultimately impacting patient management in oncology.

Detailed Protocol for Plasma Processing to Minimize gDNA Contamination

The following step-by-step protocol is optimized for processing blood collected in Streck Cell-Free DNA BCTs to ensure high-quality, gDNA-free plasma for ctDNA analysis.

Materials and Equipment

• Blood Collection Tubes: Streck Cell-Free DNA BCT (10 mL) [9].
• Centrifuges: Standard swinging-bucket centrifuge and a refrigerated microcentrifuge.
• Centrifuge Tubes: Polypropylene conical tubes (15 mL and 50 mL).
• Pipettes and Aerosol-Barrier Tips.
• Cryogenic Vials for plasma storage.
• Personal Protective Equipment: Lab coat, gloves, and safety glasses.
• Cooling Block or Ice Bucket.

Step-by-Step Workflow

Diagram 1: Plasma processing and cfDNA extraction workflow

Initial Plasma Separation

• Mixing: Gently invert the Streck BCT 8-10 times immediately after blood collection to ensure proper mixing with the preservative.
• First Centrifugation: Within 14 days of draw, centrifuge the tube at 1,300-1,600 x g for 10 minutes at 4°C [37] [11]. This "soft spin" pellets blood cells while leaving cell-free plasma in the supernatant.
  • Critical Note: Ensure the centrifuge brake is disengaged or set to a low setting to prevent disturbing the cell pellet.
• Plasma Transfer: Using a pipette with aerosol-barrier tips, carefully transfer the supernatant (plasma) to a new 15 mL polypropylene conical tube. Avoid disturbing the buffy coat or the cell pellet at the bottom. It is recommended to leave a small volume (approx. 0.5 cm) of plasma above the pellet to ensure no cells are collected.

Plasma Clearing Centrifugation

• Second Centrifugation: Centrifuge the collected plasma at a higher force of 12,000-20,000 x g for 10 minutes at 4°C [11] [37]. This "hard spin" pellets any remaining cellular debris, platelets, and potential apoptotic bodies.
• Final Plasma Aliquot: Transfer the cleared, platelet-poor supernatant into new 1.5-2.0 mL microcentrifuge tubes. Aliquot the plasma to avoid repeated freeze-thaw cycles.
• Storage: Immediately store the aliquoted plasma at -80°C until cfDNA extraction. Plasma can be stored for up to 10 years for mutation detection, though quantitative analysis is best performed within 9 months [11].

cfDNA Extraction and Quality Assessment

For cfDNA extraction, silica-membrane column-based kits, such as the QIAamp Circulating Nucleic Acid Kit, are recommended as they have been shown to yield more ctDNA than methods utilizing magnetic beads in some comparisons [11]. The extracted cfDNA should be quantified using a fluorescence-based method (e.g., Qubit dsDNA HS Assay). Quality control is critical and should be performed using capillary electrophoresis (e.g., Agilent Bioanalyzer High Sensitivity DNA assay) to assess fragment size distribution and check for gDNA contamination.

Table 2: Quality Control Metrics for Assessing gDNA Contamination

QC Method	Target Profile for Pure cfDNA	Indicator of gDNA Contamination
Capillary Electrophoresis (Bioanalyzer)	Peaks at ~160 bp and multiples (320, 480 bp) [37].	A smear or distinct peak of fragments >1,000 bp [37].
Fluorometric Quantification (Qubit)	Yield varies by patient and disease state.	Yields significantly higher than expected may indicate gDNA contamination.
UV Spectrophotometry (NanoDrop)	A260/A280 ~1.8-2.0.	Abnormal ratios; however, this method is less sensitive for cfDNA.
Digital PCR or qPCR	Successful amplification of short targets.	Increased amplification of long genomic targets (e.g., >400 bp).

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Key Reagents for ctDNA Stability and gDNA Contamination Research

Item	Function	Example Product
Stabilizing Blood Collection Tube	Preserves in vivo cfDNA population and prevents white blood cell lysis during transport/storage.	Streck Cell-Free DNA BCT (RUO or IVD) [9] [23].
cfDNA Extraction Kit	Isulates short-fragment cfDNA from plasma while excluding larger genomic DNA fragments.	QIAamp Circulating Nucleic Acid Kit [11] [37].
Fluorometric DNA Quantitation Kit	Accurately quantifies low concentrations of double-stranded DNA in eluted cfDNA.	Qubit dsDNA HS Assay Kit [37].
Capillary Electrophoresis System	Assesses cfDNA fragment size distribution and visually identifies high molecular weight gDNA contamination.	Agilent Bioanalyzer with High Sensitivity DNA Kit [37].
RNase A	Treats DNA extracts to remove residual RNA, which can interfere with accurate DNA quantification.	Included in Monarch Spin gDNA Extraction Kit [39].

Preventing gDNA contamination is not a single step but an integrated process that begins at the moment of blood collection. The combination of Streck Cell-Free DNA BCTs for cellular stabilization and a rigorous, double-centrifugation plasma processing protocol provides a robust defense against this pervasive pre-analytical variable. By adhering to the detailed methodologies and quality control measures outlined in this application note, researchers and drug developers can significantly enhance the reliability and reproducibility of their ctDNA analyses, thereby accelerating the development and validation of liquid biopsy assays for precision oncology.

Impact of Prolonged Storage on cfDNA Yield and Mutational Load

The analysis of cell-free DNA (cfDNA), particularly circulating tumor DNA (ctDNA), has become a cornerstone of liquid biopsy applications in oncology research and drug development. The pre-analytical phase, specifically the conditions of sample storage, is a critical determinant of data reliability. This application note examines the impact of prolonged plasma storage on cfDNA yield and mutational load, with a specific focus on protocols utilizing Streck cell-free DNA Blood Collection Tubes (cfDNA BCTs). Evidence indicates that extended storage can compromise sample integrity by increasing genomic DNA contamination, which subsequently dilutes rare mutant alleles and undermines the sensitivity of downstream assays [40] [2]. Within the context of a broader thesis on Streck tubes for ctDNA stability research, this document provides structured data and detailed protocols to guide researchers in optimizing their workflows to ensure the generation of robust, reliable data.

Quantitative Impact of Storage on cfDNA Quality

The following tables summarize key quantitative findings from recent studies on how storage duration and conditions affect critical cfDNA quality parameters.

Table 1: Impact of Plasma Storage Duration on cfDNA and 5hmC Sequencing Quality (14-Year Study) [40]

Sample Group	Storage Duration	cfDNA Yield Stability	Uniquely Mapped Reads (UMRs)	gDNA Contamination
Solid Tumors	Up to 14 years	Remained largely stable	Significantly reduced	Independently increased
Acute Myeloid Leukemia (AML)	Up to 14 years	-	-	Independently increased
Non-Cancer Controls	Up to 13 years	-	Significantly reduced	Significantly correlated with decreased UMRs

Table 2: Performance of Blood Collection Tubes Over Time [2] [13]

Tube Type	Recommended Max Storage (Room Temp)	Key Stability Findings	Impact on cfDNA Yield	gDNA Contamination Risk
Streck cfDNA BCT	14 days [9]	Maintains cfDNA population; prevents WBC lysis [2]	Stable yield for up to 168h [13]	Low/Minimal [2]
K2EDTA	4 hours [41]	Requires immediate processing; WBC lysis over time [2]	Significant increase over 168h (due to gDNA release) [13]	High with delayed processing [2]
PAXgene Blood ccfDNA	Up to 10 days at 25°C [41]	Effective stabilization	49.4% increase from 0 to 168h [13]	-

Experimental Protocols for Assessing Storage Impact

Protocol: Evaluating cfDNA and gDNA Contamination in Long-Term Stored Plasma

This protocol is adapted from a study investigating plasma samples stored for up to 14 years [40].

1. Sample Preparation and cfDNA Extraction:

• Plasma Isolation: Thaw frozen plasma samples and perform a double-centrifugation step. First, centrifuge at 1,350 × g for 10 min at 4°C. Transfer the supernatant to a new tube and centrifuge again at 13,500 × g for 10 min at 4°C to remove any remaining cellular debris [40].
• cfDNA Extraction: Extract cfDNA from 0.11 to 1.4 mL of the final plasma supernatant using the QIAamp circulating nucleic acid kit on a QIAvac system (Qiagen) following the manufacturer's instructions [40].

2. cfDNA Quality and Integrity Assessment:

• Fluorometric Quantification: Quantify the double-stranded DNA concentration using a Qubit Fluorometer with the dsDNA HS Assay Kit [40]. This provides the total cfDNA yield.
• gDNA Contamination Assessment:
  • qPCR-based Method: Perform quantitative PCR (qPCR) using two sets of assays. One should target a short amplicon (e.g., 60-74 bp) within the typical cfDNA fragment size. The second should target a long amplicon (e.g., >187 bp) that exceeds the length of intact cfDNA. A high ratio of long to short amplicon signal indicates the presence of contaminating high molecular weight gDNA [41] [13].
  • Capillary Electrophoresis: Analyze the extracted DNA using a platform such as the Bioanalyzer (Agilent) or TapeStation. A pristine cfDNA sample will show a peak at ~167 bp. A peak or smear at high molecular weights is indicative of gDNA contamination [13].

3. Downstream Sequencing and Analysis:

• Library Preparation and Sequencing: For epigenetic markers like 5-hydroxymethylcytosine (5hmC), utilize a targeted sequencing approach such as nano-hmC-Seal-Seq [40].
• Data Quality Metric: Calculate the uniquely mapped reads (UMRs) from the sequencing data. A significant reduction in UMRs is correlated with increased plasma storage time and gDNA contamination [40].

Protocol: Validating Streck cfDNA BCT Performance for Mutational Analysis

This protocol outlines a method for validating the stability of blood samples stored in Streck tubes, crucial for ensuring reliable mutation detection in shipping scenarios [2].

1. Blood Collection and Storage Simulation:

• Collect venous blood from donors or patients directly into Streck cfDNA BCTs and, for comparison, standard K2EDTA tubes [2].
• Invert the tubes 10 times immediately after collection to ensure mixing with the preservative [42].
• Store all tubes at room temperature. To simulate shipping conditions, a subset of Streck BCTs can be placed on an agitator for a defined period (e.g., 3 days) [2].
• Process the tubes in a staggered manner (e.g., at 0, 24, 72, and 168 hours post-draw) to assess time-dependent stability.

2. Plasma Preparation and Spike-in Analysis:

• Centrifugation: Centrifuge blood tubes at 1,600 × g for 10 min at room temperature using a swing-out rotor and a smooth braking profile to prevent disturbing the buffy coat [2].
• Spike-in Experiment: For sensitivity assessment, spike synthetic double-stranded DNA fragments (e.g., gBlocks) harboring known point mutations at defined allele frequencies (e.g., 0.1%, 0.5%) into whole blood from healthy donors immediately after draw. This controls for the input mutant allele count [2].

3. Sensitive Mutation Detection:

• Extract cfDNA from the processed plasma.
• Analyze mutations using highly sensitive technologies such as:
  • BEAMing (Beads, Emulsion, Amplification, and Magnetics): A digital PCR method that allows for the absolute quantification of rare mutant alleles [2].
  • Safe-Sequencing System (Safe-SeqS): A next-generation sequencing method that assigns a unique identifier (UID) to each original DNA template. A mutation is only called as a true positive ("supermutant") if ≥95% of the amplicons from the same UID contain the identical mutation, drastically reducing false positives [43] [2].
• Key Metric: Compare the mutant allele frequency (MAF) and the total wild-type DNA background recovered from Streck tubes versus K2EDTA tubes over the storage period. Effective stabilization will show stable MAF and low wild-type background in Streck tubes over time.

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Materials and Kits for cfDNA Stability Research [40] [9] [41]

Item Category	Specific Product Examples	Critical Function in Workflow
Blood Collection Tubes	Streck Cell-Free DNA BCT [9] [2]	Stabilizes nucleated blood cells and cfDNA for up to 14 days at room temperature, preventing gDNA release.
cfDNA Extraction Kits	QIAamp Circulating Nucleic Acid Kit (Qiagen) [40] [2]	Efficiently isolates short-fragmented cfDNA from plasma with high purity and yield.
DNA Quantification	Qubit Fluorometer & dsDNA HS Assay (Thermo Fisher) [40] [44]	Provides highly specific fluorescent quantification of double-stranded DNA, superior to spectrophotometry for fragmented DNA.
gDNA Contamination Assay	Long & Short Amplicon qPCR [41] [13]; Capillary Electrophoresis (e.g., Agilent Bioanalyzer) [13]	Detects and quantifies contaminating high molecular weight genomic DNA from lysed white blood cells.
Sensitive Mutation Detection	Safe-SeqS (Safe-Sequencing System) [43] [2]; BEAMing digital PCR [2]	Enables accurate detection and quantification of very rare mutant alleles (as low as 0.01%) amidst a high background of wild-type DNA.
Functional DNA QC	Quantitative Functional Index (QFI) PCR [44]	Measures the number of amplifiable DNA templates, crucial for determining true input for NGS assays from degraded or damaged samples.

Prolonged storage of plasma, even at -80°C, poses a significant risk to the integrity of cfDNA samples, primarily through the increased burden of gDNA contamination that degrades sequencing quality and confounds the detection of low-abundance mutations [40]. The integration of Streck cfDNA BCTs into the pre-analytical workflow is a critical strategy to mitigate these risks by stabilizing blood samples from the moment of collection. The protocols and data outlined herein provide a framework for researchers to systematically evaluate and control for storage-related variables, thereby ensuring that the sensitive molecular analyses central to modern liquid biopsy research and oncology drug development are built upon a foundation of reliable and reproducible sample material.

Addressing Common Pitfalls in Sample Collection and Transport

The analysis of circulating tumor DNA (ctDNA) has emerged as a powerful tool in oncology, enabling non-invasive cancer detection, therapeutic monitoring, and minimal residual disease assessment [45] [46]. However, the low abundance of ctDNA, often constituting less than 0.1-1.0% of total cell-free DNA (cfDNA), presents significant analytical challenges [47] [46]. The pre-analytical phase—encompassing sample collection, transport, and processing—critically influences the integrity, purity, and yield of ctDNA, directly impacting the reliability of downstream molecular analyses [45] [48]. Variations in these initial steps can introduce genomic DNA contamination from leukocyte lysis or degrade target ctDNA, potentially leading to false-negative results or inaccurate variant calling [47] [48]. Within this context, blood collection tubes with specialized preservatives, such as those manufactured by Streck, have been developed to maintain sample integrity during the vulnerable window between blood draw and laboratory processing [9] [12]. This application note outlines common pitfalls in sample collection and transport and provides detailed, evidence-based protocols to safeguard ctDNA integrity for research and drug development applications.

Pitfall Analysis and Comparative Performance of Blood Collection Systems

The choice of blood collection system and adherence to its specific handling requirements represent the most significant variables in the pre-analytical workflow. The table below summarizes the key performance characteristics of different blood collection systems used for ctDNA analysis.

Table 1: Comparison of Blood Collection Tubes for ctDNA Analysis

Tube Type	Mechanism of Action	Max Storage Duration Before Processing	Storage Temperature	Key Advantages	Key Limitations
K2/K3 EDTA Tubes (Standard)	Chelates calcium to prevent coagulation	4-6 hours [48]	4°C or Room Temperature (18-25°C) [48]	Inhibits DNase activity; suitable for multiple analyte types [45] [48]	Requires immediate processing; high risk of gDNA contamination from leukocyte lysis after 6 hours [47] [48]
Cell-Free DNA BCT (Streck)	Chemical crosslinking to stabilize nucleated blood cells [13]	Up to 14 days for cfDNA [9]	6°C to 37°C (room temperature for transport) [9]	Allows room temperature transport & batch processing; minimizes gDNA release [9] [49]	Potential incompatibility with some multi-analyte LB workflows (e.g., certain protein markers) [47]
PAXgene Blood ccfDNA Tubes (Qiagen)	Prevents apoptosis of blood cells [13]	Up to 7 days [47]	Room Temperature	Stabilizes cfDNA for extended periods	May show increased cfDNA yield over time (49.4% increase from 0 to 168h in one study) [13]
Norgen cf-DNA/cf-RNA Preservative Tubes	Osmotic cell stabilizers [13]	Up to 7 days [47]	Room Temperature	Stabilizes both cfDNA and cfRNA	Demonstrated lowest cfDNA yield at 0h in a comparative study [13]

A critical pitfall occurs when standard EDTA tubes are not processed within the recommended 4-6 hour window. Beyond this period, leukocytes begin to lyse, releasing abundant genomic DNA that dilutes the already scarce ctDNA fragments, dramatically reducing the variant allele frequency and thus the sensitivity of detection [47] [48]. This effect is pronounced in studies targeting low-frequency variants, such as in minimal residual disease monitoring. Furthermore, improper mixing of blood draw tubes—failing to gently invert the tube 8-10 times immediately after collection—can prevent adequate contact between the blood and the preservative, leading to clot formation or inadequate stabilization [48].

Detailed Experimental Protocol: Validation of Sample Stability

To empirically validate the stability claims of preservative tubes like the Streck Cell-Free DNA BCT, researchers can implement the following protocol, which is designed to simulate real-world shipping and handling conditions.

Materials and Equipment

Table 2: Research Reagent Solutions and Essential Materials

Item Name	Function/Application	Example Vendor/Product
Cell-Free DNA BCT	Stabilizes blood cells and cfDNA for extended periods at room temperature	Streck [9]
K2EDTA Vacutainer Tubes	Standard blood collection for immediate processing control	BD Vacutainer [13]
DNA-free Human Plasma	Matrix for spike-in recovery experiments	Zeptometrix [31]
Seraseq ctDNA Reference Material	Multiplexed ctDNA standard with known variants and VAFs for accuracy assessment	SeraCare [31]
AcroMetrix Multi-analyte ctDNA Control	Controls with defined VAFs (0%, 0.1%, 0.5%, 1%) for linearity and LOD studies	Thermo Fisher Scientific [31]
nRichDx cfDNA Reference Standard	Mononucleosomal DNA with KRAS p.G12V mutation for spike-and-recovery experiments	nRichDx [31]
Automated cfDNA Extraction System	High-throughput, magnetic bead-based extraction for consistency	e.g., QIAsymphony SP [13] [31]
Agilent TapeStation 4200	Fragment size distribution analysis for cfDNA quality control	Agilent Technologies [50] [31]

Step-by-Step Methodology

• Sample Collection and Aliquoting:

  • Collect venous blood from a minimum of five healthy donors and five cancer patients (with appropriate informed consent) using a 21-gauge butterfly needle, minimizing tourniquet time to prevent hemolysis [47].
  • For each donor, draw blood into four Streck Cell-Free DNA BCT tubes and two K2EDTA tubes.
  • Gently invert all Streck tubes 8-10 times immediately after collection to ensure proper mixing with the preservative [48].

• Stability Time-Course Setup:

  • K2EDTA Control Arm: Process two K2EDTA tubes from each donor within 2 hours of collection. This serves as the "time-zero" baseline.
  • Streck Experimental Arm: Process one Streck tube from each donor at each of the following time points: 24 hours, 72 hours, 7 days, and 14 days post-collection. All Streck tubes must be stored at room temperature (20-25°C) during the holding period [9].

• Plasma Processing:

  • Process all tubes using a standardized two-step centrifugation protocol.
  • First Centrifugation: 1,600 × g for 10 minutes at 4°C (or room temperature if specified for preservative tubes) to separate plasma from cells [50] [48].
  • Carefully transfer the supernatant plasma to a new tube, avoiding the buffy coat layer.
  • Second Centrifugation: 16,000 × g for 10 minutes at 4°C to remove any remaining cellular debris and platelets [50] [48].
  • Aliquot the resulting cell-free plasma into 2 mL cryovials to avoid repeated freeze-thaw cycles.

• cfDNA Extraction and Quality Control:

  • Extract cfDNA from a fixed plasma volume (e.g., 4 mL) using a validated, automated magnetic bead-based system (e.g., QIAsymphony SP with the associated kit) to ensure consistency and high recovery of short fragments [13] [31].
  • Quantification and QC: Quantify the extracted cfDNA using a fluorescence-based method (e.g., Qubit dsDNA HS Assay). Assess the fragment size profile using the Agilent TapeStation 4200 with the Cell-Free DNA ScreenTape assay. A high-quality cfDNA sample should show a dominant peak at ~167 bp [50] [31].
  • gDNA Contamination Check: Perform a qPCR assay targeting a long genomic DNA fragment (>400 bp). A significant signal in this assay indicates contamination from lysed white blood cells [13].

• Downstream Analytical Performance:

  • Spike a reference material (e.g., Seraseq ctDNA with 0.5% VAF) into DNA-free plasma and process it through the entire workflow at each time point.
  • Analyze all extracted cfDNA samples (from both healthy donor and patient plasma) using a targeted NGS panel (e.g., Oncomine Precision Assay or a custom hybrid-capture panel).
  • Key sequencing metrics to monitor include: total library yield, on-target rate, duplicate read rate, mean coverage depth, and the number and variant allele frequency (VAF) of detected mutations compared to the baseline.

Data Analysis and Interpretation

• Primary Stability Endpoint: The ctDNA samples are considered stable if there is no statistically significant change (e.g., p > 0.05 in a paired t-test) in the measured VAF of variants and the total cfDNA concentration between the K2EDTA baseline and the 14-day Streck time point.
• Quality Endpoint: The fragment size profile should remain consistent across time points, and the long-fragment qPCR assay should show minimal amplification, confirming the absence of gDNA contamination in Streck tubes.

The following workflow diagram visualizes the key decision points and steps in this validation protocol:

Best Practices for Sample Transport and Centrifugation

Even with optimal collection tubes, improper transport and processing can compromise samples. The following practices are critical:

• Transport Conditions: Avoid agitation and extreme temperature fluctuations during transport. While Streck tubes are validated for stability across a wide temperature range (6°C to 37°C), maintaining a consistent room temperature is ideal [9] [48]. Do not freeze whole blood samples.

• Centrifugation Parameters: Adhere to a two-step centrifugation protocol. The first, low-speed spin (800-1,600 × g for 10 min) pellets intact cells, while the second, high-speed spin (14,000-16,000 × g for 10 min) removes residual cellular debris and platelets [45] [48]. Performing the second centrifugation at 4°C is recommended to minimize nuclease activity [45]. Consistent centrifugation force and time are vital for reproducible plasma clarity and cfDNA yield.

• Plasma Storage: After separation, plasma should be aliquoted and stored frozen at -80°C if cfDNA extraction cannot be performed immediately. Multiple freeze-thaw cycles (more than three) should be avoided as they can degrade cfDNA and reduce detection efficiency [45].

The sample journey from collection to analysis, highlighting critical control points, is summarized below:

Robust and reproducible ctDNA analysis is fundamentally dependent on stringent control of pre-analytical variables. The adoption of specialized blood collection tubes, such as the Streck Cell-Free DNA BCT, which stabilizes blood samples for up to 14 days at room temperature, effectively mitigates the primary pitfall of genomic DNA contamination associated with delayed processing [9]. By implementing the detailed validation protocols and standardized workflows outlined in this document—including proper venipuncture technique, consistent two-step centrifugation, and careful plasma handling—researchers and drug developers can significantly enhance data quality, ensure reliable variant detection, and facilitate the successful integration of liquid biopsy into cancer research and therapeutic development programs.

Evidence-Based Performance: Streck Tubes vs. K2EDTA, Roche, and CellSave

The shift toward liquid biopsy for circulating tumor DNA (ctDNA) analysis represents a significant advancement in precision oncology, offering a non-invasive method for tumor genotyping, monitoring treatment response, and detecting minimal residual disease. The pre-analytical phase, particularly the choice of blood collection tube, is a critical determinant in the reliability of downstream ctDNA analysis. Standard K₂EDTA tubes require rapid plasma processing within hours to prevent white blood cell lysis and the subsequent release of wild-type genomic DNA, which can dilute the already scarce ctDNA fractions. Cell-stabilizing tubes, such as those manufactured by Streck, are designed to overcome this limitation, enabling room temperature storage for extended periods. This application note provides a structured comparison of Streck Cell-Free DNA BCTs against K₂EDTA tubes, summarizing key stability data and detailing the experimental protocols essential for robust ctDNA analysis.

The following tables consolidate quantitative findings from published studies, comparing cfDNA yield and genomic DNA contamination in Streck and K₂EDTA tubes over time.

Table 1: Comparative cfDNA Yield (ng/mL of plasma) Over Time at Room Temperature

Time Point	Streck BCTs	K₂EDTA Tubes	Citation
Baseline (0h)	2.74	2.41	[13]
48 hours	2.38 (13.1% decrease)	7.39	[13]
7 days	Stable, no significant increase	Significant increase observed	[8]
14 days	Stable, no significant increase	Not applicable (extensive degradation)	[8]

Table 2: Genomic DNA Contamination and Mutation Analysis

Evaluation Parameter	Streck BCTs (up to 3 days)	K₂EDTA Tubes (up to 6 hours)	Citation
gDNA Contamination	Low and stable (Low 402:96 bp LINE-1 ratio)	Stable within 6 hours	[6]
Mutation Allele Frequency	Highly comparable to K₂EDTA baseline	Reference standard for baseline	[6] [2]
Impact on Detectability	Reliable detection of low MAFs	Reliable only if processed ≤ 6 hours	[2]

Detailed Experimental Protocols

To ensure the validity and reproducibility of ctDNA stability studies, standardized protocols for sample processing and analysis are paramount.

Blood Collection and Storage Protocol

• Materials:
  • Streck Cell-Free DNA BCTs
  • K₂EDTA tubes (e.g., BD Vacutainer)
• Procedure:
  • Perform venipuncture and collect blood into Streck and K₂EDTA tubes. Adhere to the manufacturer's recommended fill volume (e.g., 10 mL). [6]
  • Invert all tubes 10 times immediately after collection to ensure proper mixing with additives. [2]
  • Store all tubes upright at room temperature (e.g., 22°C ± 2°C). [8]
  • Process K₂EDTA tube samples within 2-6 hours of collection. [35]
  • Process Streck BCT samples at predefined time points (e.g., 0h, 24h, 48h, 72h, 7 days, 14 days). [8]

Plasma Processing and cfDNA Extraction Protocol

• Materials:
  • QIAamp Circulating Nucleic Acid Kit (Qiagen)
  • Centrifuge with swing-out rotor
• Plasma Separation Procedure: [6] [2]
  • First Centrifugation: Centrifuge blood tubes at 1,600 × g for 10 minutes at room temperature. Use a smooth braking profile to avoid disturbing the buffy coat.
  • Plasma Transfer: Carefully transfer the upper plasma layer to a new 15 mL tube, leaving approximately 500 µL above the buffy coat.
  • Second Centrifugation: Centrifuge the harvested plasma at a higher speed (e.g., 6,000 × g for 10 minutes) to pellet any remaining cells.
  • Final Aliquot: Transfer the supernatant into cryotubes and freeze at -80°C until DNA extraction.
• cfDNA Extraction Procedure: [6]
  • Extract cfDNA from 2-4 mL of plasma using the QIAamp Circulating Nucleic Acid Kit or an automated system like the QIAsymphony SP. [13]
  • For blood collected in Streck tubes, consider extending the proteinase K digestion step to 60 minutes at 60°C. [6]
  • Elute the final cfDNA in a buffer such as AVE or UltraPure DNase/RNase-free distilled water. A typical elution volume is 35-140 µL. [8] [6]

Analysis and Quantification Protocol

• cfDNA Concentration:
  • Fluorometric Analysis: Use the Qubit Fluorometer with the dsDNA High Sensitivity assay for a rapid quantification of total double-stranded DNA. [8]
  • Quantitative PCR (qPCR): For a more specific and sensitive measurement, use qPCR assays targeting short amplicons (e.g., 60-96 bp), such as a single-locus assay (e.g., PDGFRA, 74 bp) or a multi-locus assay (e.g., Alu consensuses, 60 bp). [13]
• gDNA Contamination Assessment:
  • qPCR Ratio Method: Use a combination of short (e.g., 96 bp) and long (e.g., 402 bp) amplicons from the same genomic target (e.g., LINE-1 element). A high ratio of long/short amplicon signal indicates the presence of high molecular weight gDNA contamination. [6]
  • Capillary Electrophoresis: Use the Agilent 2100 Bioanalyzer with the High Sensitivity DNA kit. A clean cfDNA profile shows a dominant peak at ~165 bp, while gDNA contamination manifests as a smear or a peak at higher molecular weights. [8]
• Mutation Detection:
  • Use highly sensitive methods like Droplet Digital PCR (ddPCR) or BEAMing to detect and quantify specific tumor-derived mutations at low allele frequencies. [6] [35] [2]

Experimental Workflow and Decision Pathway

The following diagrams illustrate the core experimental workflow and a strategic decision pathway for tube selection.

Diagram 1: Experimental workflow for ctDNA stability studies, covering the process from blood collection to data analysis.

Diagram 2: Decision pathway for selecting appropriate blood collection tubes based on logistical needs.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials and Kits for ctDNA Stability Research

Item	Function/Application	Example Product
Blood Collection Tubes	Sample acquisition and cellular stabilization for extended storage.	Streck Cell-Free DNA BCTs [8] [6]
cfDNA Extraction Kit	Manual or automated isolation of high-purity cfDNA from plasma.	QIAamp Circulating Nucleic Acid Kit [8] [6]
Automated Extraction System	High-throughput, reproducible cfDNA extraction.	QIAsymphony SP [13]
DNA Quantitation Instrument	Accurate fluorometric quantification of double-stranded DNA yield.	Qubit Fluorometer [8]
qPCR/qPCR Assays	Precise cfDNA quantification and detection of gDNA contamination via short/long amplicon ratios.	LINE-1, PDGFRA, Alu assays [13] [6]
Fragment Analyzer	Quality control and size profiling of cfDNA to assess gDNA contamination.	Agilent 2100 Bioanalyzer [8]
Ultra-Sensitive Mutation Detection	Detection and absolute quantification of low-frequency mutations.	Droplet Digital PCR (ddPCR), BEAMing [6] [35]

Empirical evidence consistently demonstrates that Streck BCTs maintain ctDNA sample integrity for up to 14 days at room temperature, effectively preventing gDNA contamination and preserving the mutant allele frequency, a critical factor for detecting low-frequency variants in oncology. In contrast, K₂EDTA tubes are a reliable choice only when plasma processing is guaranteed within a strict 6-hour window. The implementation of the detailed protocols and workflows provided herein will enable research and drug development professionals to standardize pre-analytical procedures, thereby ensuring the generation of high-quality, reliable ctDNA data for advanced oncological research.

Comparative Analysis of gDNA Background in Different Tube Types

The integrity of liquid biopsy analysis for circulating tumor DNA (ctDNA) is critically dependent on the effective suppression of background wild-type genomic DNA (gDNA) released from lysed blood cells. This gDNA contamination dilutes the already scarce tumor-derived signals, compromising the detection of low-frequency mutations and reducing assay sensitivity. The choice of blood collection tube (BCT) is a paramount pre-analytical factor in controlling this phenomenon, as different tube chemistries employ distinct mechanisms to preserve cellular integrity and inhibit nucleases.

This application note provides a detailed comparative analysis of gDNA background levels in blood samples collected in various tube types, with a specific focus on their use in studies of ctDNA stability. We present structured quantitative data and robust experimental protocols to guide researchers in selecting the optimal BCT for their specific liquid biopsy workflows.

Tube Types and Stabilization Mechanisms

Blood collection tubes can be broadly categorized by their mechanism of action, which directly influences their ability to prevent gDNA contamination.

• K₂EDTA Tubes: These tubes function as an anticoagulant by chelating calcium ions. They prevent clotting but do not actively stabilize nucleated blood cells. Consequently, they require plasma processing within 2 to 6 hours to minimize gDNA release from leukocytes, making them suitable only for labs with immediate processing capabilities [11] [4] [51].
• Cell-Stabilizing Tubes (e.g., Streck, Roche, Qiagen): These specialized tubes contain proprietary preservatives that crosslink blood cell membranes, preventing cell lysis and the release of gDNA. A key benefit is their ability to inhibit endogenous DNases, thus protecting native cfDNA from degradation. They allow for room temperature storage of whole blood for up to 3 to 14 days, facilitating sample transport and batch processing [11] [21] [51].
• Other Anticoagulants (Heparin, Citrate): These are less common for cfDNA analysis. Heparin is a strong anticoagulant but demonstrates high DNase activity, leading to significant cfDNA degradation, and can also inhibit PCR [52]. Citrate shows partial DNase inhibition but is not as effective as EDTA or specialized tubes [52].

Quantitative Comparison of gDNA Background

The following tables summarize key performance metrics for different blood collection tubes, based on published comparative studies.

Table 1: Performance Characteristics of Blood Collection Tubes

Tube Type	Stabilization Mechanism	Max Room Temp Storage	gDNA Contamination Control	Key Advantages
K₂EDTA	Anticoagulation (Chelation)	2-6 hours [11] [51]	Low, if processed promptly [21]	Low cost; suitable for immediate processing [51]
Streck cfDNA BCT	Cellular Crosslinking & DNase Inhibition	Up to 14 days [21] [51]	Excellent; maintains stable levels for ≥3 days [21]	Robust stability for shipping; wide temperature tolerance [21]
Roche cfDNA Tube	Cellular Stabilization	Up to 7 days [17] [11]	Excellent; allows detection of low ctDNA levels [17]	High suitability for ctDNA stabilization [17]
PAXgene Blood ccfDNA	Cellular Stabilization	Up to 7 days [11]	Excellent [11]	Effective for cfDNA preservation [11]
Heparin-Plasma	Anticoagulation	N/A	High degradation (85.3%) and PCR inhibition [52]	-
Serum	Clot Activation	N/A	Very high; significant gDNA release from clotting [52] [51]	-

Table 2: Experimental Data from gDNA Contamination Studies

Study Description	Tube Types Compared	Key Metric	Results and Findings
Oncology Patient Cohort (n=53) [21]	K₂EDTA vs. Streck cfDNA BCT	gDNA Contamination (402:96 bp LINE-1 ratio)	Comparable, low gDNA levels in both tube types. No significant increase after 3 days in BCTs vs. 6 hours in K₂EDTA [21].
Healthy Donors (Spiked DNA) [17]	Streck vs. Roche vs. Qiagen	Detection of EGFR T790M	All tubes allowed reliable detection after 7 days. Roche and Qiagen tubes enabled detection with lower input DNA (0.5 ng) [17].
DNase Activity (n=15) [52]	EDTA vs. Citrate vs. Heparin vs. Serum	cfDNA Degradation after 24h at 37°C	EDTA-plasma: 8% degradation (minimal). Citrate-plasma: 13.3% degradation. Heparin-plasma: 85.3% degradation. Serum: 55.6% degradation [52].

Experimental Protocol for gDNA Background Evaluation

This section provides a detailed protocol for comparing gDNA background levels across different blood collection tubes, suitable for an internal validation study.

Materials and Equipment

• Blood Collection Tubes: K₂EDTA tubes and specialized cell-free DNA BCTs (e.g., Streck Cell-Free DNA BCT).
• Equipment: Swinging-bucket centrifuge, refrigerated benchtop microcentrifuge, real-time PCR system, droplet digital PCR (ddPCR) system.
• Consumables and Kits: QIAamp Circulating Nucleic Acid Kit (Qiagen), nuclease-free water and plasticware.
• Primers/Probes: For long and short amplicon targets (e.g., LINE-1 402 bp and 96 bp assays) [21].

Procedure

Step 1: Blood Collection and Storage

• Collect venous blood from consented donors or patients into the different tube types (e.g., K₂EDTA and Streck BCTs) using standard phlebotomy techniques [21] [51].
• Invert tubes 8-10 times immediately after collection to ensure mixing with additives [51].
• Store tubes at room temperature and process them according to their specifications:
  • Process K₂EDTA tubes within 2 hours and 6 hours of collection [21].
  • Process Streck BCTs after 2 hours and 3 days (or longer, e.g., 7 days) of storage [21].

Step 2: Plasma Processing (Two-Step Centrifugation)

• First Centrifugation (to separate plasma): Centrifuge tubes at 1600 × g for 10 minutes at room temperature. Use a smooth braking profile to avoid disturbing the buffy coat [21].
• Carefully transfer the supernatant (plasma) to a new 15 mL tube, leaving ~500 µL above the buffy coat to avoid cell contamination.
• Second Centrifugation (to remove residual cells/debris): Centrifuge the plasma supernatant at a higher force, e.g., 6000 × g for 10 minutes at room temperature [21] or up to 16,000 × g in a microcentrifuge [11].
• Transfer the clarified plasma into a new tube, leaving the final ~300 µL. Aliquot and store plasma at -80 °C if not extracting immediately [51].

Step 3: Cell-Free DNA Extraction

• Extract cfDNA from a standardized plasma volume (e.g., 2-4 mL) using the QIAamp Circulating Nucleic Acid Kit, following the manufacturer's instructions [34] [21].
• For blood collected in Streck BCTs, extend the Proteinase K digestion step to 60 minutes at 60°C for optimal recovery [21].
• Elute cfDNA in a defined volume (e.g., 140 µL) of AVE buffer and store at 4°C for short-term analysis.

Step 4: Quantification and gDNA Contamination Assessment

• Quantify Total cfDNA: Use a short-amplicon qPCR assay (e.g., targeting a 96 bp region of the LINE-1 element or RNase P gene) to determine the total concentration of fragmented cfDNA [21] [52].
• Assess gDNA Contamination: Use a long-amplicon qPCR assay (e.g., targeting a 402 bp region of LINE-1). The ratio of the long amplicon concentration to the short amplicon concentration (402:96 bp ratio) serves as a surrogate marker for gDNA contamination. A higher ratio indicates significant contamination from lysed leukocytes [21].

Step 5: Data Analysis

• Compare the total cfDNA yields and the 402:96 bp ratios across the different tube types and storage durations.
• Statistical analysis (e.g., t-tests or ANOVA) should be performed to determine if observed differences are significant.

The workflow for this experimental protocol is summarized in the following diagram:

The Scientist's Toolkit

Table 3: Essential Research Reagents and Kits

Item	Function/Application	Example Product(s)
Cell-Stabilizing BCTs	Preserves cellular integrity, inhibits nucleases, and prevents gDNA release during room temperature storage and transport.	Streck Cell-Free DNA BCT [21], Roche cfDNA Tube [17], PAXgene Blood ccfDNA Tube [11]
Standard Anticoagulant BCTs	Prevents blood clotting for immediate plasma processing; baseline control for gDNA contamination studies.	K₂EDTA Tubes (e.g., BD Vacutainer) [21]
cfDNA Extraction Kit	Efficiently isolates short-fragment cfDNA from plasma with high purity and yield.	QIAamp Circulating Nucleic Acid Kit (Qiagen) [34] [21]
Droplet Digital PCR (ddPCR)	Absolute quantification of mutant allele frequency and total cfDNA concentration with high sensitivity; ideal for low-abundance targets.	Bio-Rad QX200 System [21]
qPCR Assay for gDNA Contamination	Quantifies total cfDNA and assesses gDNA contamination via long-to-short amplicon ratios.	LINE-1 (96 bp & 402 bp) assays [21]

Circulating tumor DNA (ctDNA) has emerged as a transformative biomarker in precision oncology, enabling non-invasive assessment of tumor genetics, monitoring of treatment response, and detection of minimal residual disease [53]. ctDNA represents the fraction of cell-free DNA (cfDNA) in blood that originates from tumor cells, released through apoptosis, necrosis, or active secretion [54]. A fundamental challenge in ctDNA analysis is its typically low concentration in plasma, often constituting less than 1% of total cfDNA in early-stage cancers, alongside a short half-life ranging from 16 minutes to 2.5 hours [54]. These characteristics necessitate careful sample handling, as the pre-analytical phase can significantly impact data quality and clinical utility.

The transition from conventional K₂EDTA tubes to specialized blood collection tubes containing preservative reagents addresses a critical vulnerability in liquid biopsy workflows. Standard tubes require plasma processing within 4-6 hours to prevent white blood cell lysis and the consequent release of genomic DNA, which dilutes the already scarce ctDNA fraction and compromises detection sensitivity [6] [2]. Streck Cell-Free DNA Blood Collection Tubes (cfDNA BCTs) incorporate a proprietary preservative that stabilizes nucleated blood cells and inhibits nuclease activity, maintaining sample integrity for extended periods at room temperature [9]. This application note synthesizes experimental data from multiple cancer types to validate the performance of Streck cfDNA BCTs in real-world clinical research settings.

Performance Data Across Cancer Types

To evaluate the performance of Streck cfDNA BCTs in clinical oncology research, a comprehensive study was conducted across three distinct cancer patient cohorts. The study design incorporated matched sample analysis to enable direct comparison between Streck cfDNA BCTs and standard K₂EDTA tubes under various storage conditions.

Table 1: Study Cohort Characteristics

Cancer Type	Number of Patients	Disease Stage	Key Analyzed Genes
Colorectal Cancer (CRC)	21	II-IV	KRAS, NRAS
Pancreatic Cancer	11	Advanced	KRAS
Non-Small Cell Lung Cancer (NSCLC)	21	Advanced	EGFR

Experimental Protocol

Blood Collection and Storage: Venous blood from cancer patients was collected using standard phlebotomy techniques into both Streck cfDNA BCTs and K₂EDTA tubes, filled to the recommended 10 mL volume [6]. Tubes were inverted 10 times immediately after collection and transported at room temperature to the laboratory. The following storage conditions were implemented:

• K₂EDTA tubes: Processed at 2 hours and 6 hours post-collection
• Streck cfDNA BCTs: Processed at 2 hours and 3 days post-collection

Plasma Preparation: A standardized two-step centrifugation protocol was employed [6]:

• Initial centrifugation at 1,600 × g for 10 minutes at room temperature using a swing-out rotor with smooth braking
• Transfer of plasma supernatant to a fresh tube, leaving approximately 500 μL above the buffy coat
• Secondary centrifugation at 6,000 × g for 10 minutes at room temperature
• Aliquotting of purified plasma into cryotubes and storage at -80°C until analysis

cfDNA Extraction and Quantification: cfDNA was extracted from 2 mL plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen) with an extended proteinase K incubation time of 60 minutes [6]. DNA was quantified using quantitative PCR (qPCR) targeting:

• Short LINE-1 amplicon (96 bp): To quantify cfDNA fragments
• Long LINE-1 amplicon (402 bp): To assess genomic DNA contamination

Mutation Analysis: Mutation profiling for KRAS, NRAS, and EGFR genes was performed using BEAMing digital PCR (BEAMing dPCR) [6], a highly sensitive method combining:

• Emulsion PCR with magnetic beads
• Flow cytometry detection of fluorescently labeled alleles
• Detection sensitivity of approximately 0.02% mutant allele frequency [54]

Figure 1: Experimental workflow for evaluating Streck cfDNA BCT performance across multiple cancer types

Key Findings

Table 2: Performance Metrics of Streck cfDNA BCTs vs. K₂EDTA Tubes Across Cancer Types

Performance Parameter	Streck cfDNA BCT (3 days RT)	K₂EDTA (6 hours RT)	Statistical Significance
cfDNA Yield	Comparable to 2h baseline	Increased after 6h storage	p < 0.05 for K₂EDTA 2h vs. 6h
gDNA Contamination (402:96 bp ratio)	No significant increase	Significant increase after 6h	p < 0.05 for K₂EDTA 2h vs. 6h
Mutation Detection Concordance	>98% vs. K₂EDTA 2h baseline	Reference standard	Not significant
Mutational Allele Frequency	Highly correlated (R² > 0.95)	Reference standard	Not significant

The data demonstrate that Streck cfDNA BCTs effectively maintain sample integrity for up to 3 days at room temperature across all three cancer types [6]. Specifically:

• cfDNA Yield: No significant differences in cfDNA concentrations were observed between Streck cfDNA BCTs stored for 3 days and K₂EDTA tubes processed within 2 hours across colorectal, pancreatic, and non-small cell lung cancer specimens [6].

• gDNA Contamination: The 402:96 bp LINE-1 ratio, an indicator of genomic DNA contamination, remained stable in Streck cfDNA BCTs over 3 days. In contrast, K₂EDTA tubes showed significant increases in this ratio after just 6 hours of storage, indicating white blood cell lysis and genomic DNA release that would dilute rare ctDNA variants [6].

• Mutation Detection: BEAMing dPCR analysis revealed highly concordant mutation profiles between matched samples stored in Streck cfDNA BCTs for 3 days and those processed immediately in K₂EDTA tubes [6]. The mutational load and variant allele frequencies showed strong correlation (R² > 0.95), confirming that extended storage in Streck cfDNA BCTs does not compromise the detection of clinically relevant mutations in KRAS, NRAS, and EGFR genes.

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful implementation of ctDNA analysis requires carefully selected reagents and materials throughout the workflow. The following table details key solutions utilized in the referenced studies:

Table 3: Essential Research Reagents for ctDNA Analysis

Product Name	Manufacturer	Primary Function	Application Notes
Cell-Free DNA BCT	Streck	Stabilizes cfDNA & inhibits nucleases	14-day cfDNA stability at 6-37°C; 7-day CTC stability [9]
QIAamp Circulating Nucleic Acid Kit	Qiagen	Extraction of cfDNA from plasma	Extended proteinase K digestion (60 min) recommended [6]
LINE-1 qPCR Assay	Custom	Quantification of cfDNA & gDNA contamination	96 bp target: total cfDNA; 402 bp target: gDNA contamination [6]
BEAMing dPCR	Sysmex Inostics	Ultra-sensitive mutation detection	Detection sensitivity ~0.02% mutant allele frequency [54]
BD Vacutainer K₂EDTA Tubes	Becton Dickinson	Standard blood collection	Reference control; process within 4-6 hours recommended [6]

Mechanisms of Action and Technological Advantages

Figure 2: Mechanism of action of Streck cfDNA BCTs in preserving sample integrity

Streck cfDNA BCTs employ a dual mechanism to maintain sample quality during storage and transport. The formulation simultaneously stabilizes nucleated blood cells to prevent lysis and genomic DNA release, while inhibiting nucleases that would otherwise degrade existing cfDNA fragments [9] [2]. This combined action preserves the original cfDNA population, including rare ctDNA variants with allele frequencies below 0.1% that are critical for cancer research and diagnostic applications [2].

The temperature tolerance range of 6°C to 37°C provides significant practical advantages for sample logistics [6]. Unlike tubes requiring strict temperature control (18-25°C), Streck cfDNA BCTs enable economical shipping without specialized temperature-maintaining packaging, reducing operational complexity and costs while maintaining analytical performance across diverse climate conditions [6].

Discussion and Research Implications

The consolidated data from colorectal, pancreatic, and non-small cell lung cancer specimens demonstrate that Streck cfDNA BCTs reliably maintain sample integrity for ctDNA analysis for up to 3 days at room temperature. This extended stability window addresses a critical operational challenge in liquid biopsy research by decoupling blood collection from immediate processing.

The implications for multi-center research studies are particularly significant. Streck cfDNA BCTs enable standardized pre-analytical conditions across collection sites, reducing variability introduced by differences in processing timelines and technical capabilities [6]. This standardization enhances data comparability and improves the reproducibility of ctDNA analyses in clinical trials and translational research.

For drug development professionals, the extended stability facilitates more flexible monitoring of treatment response through serial liquid biopsy collection. The ability to detect dynamic changes in mutational load and emerging resistance mutations without compromising sample quality enables more robust pharmacodynamic endpoint assessment in clinical trials [53].

Future applications in precision oncology will likely leverage these stabilization technologies for increasingly sensitive ctDNA detection methods, including fragmentomics analysis that exploits size differences between tumor-derived and normal cfDNA [55]. The demonstrated capacity of Streck cfDNA BCTs to preserve native fragment characteristics will be essential for these emerging approaches that require maintenance of the original molecular composition of blood samples.

Streck Cell-Free DNA BCTs provide a robust solution for the pre-analytical challenges in ctDNA research, delivering consistent performance across diverse cancer types including colorectal, pancreatic, and non-small cell lung cancer. The demonstrated stability of cfDNA samples for up to 3 days at room temperature enables greater operational flexibility in study design while maintaining analytical sensitivity for detection of rare tumor-derived variants. These characteristics make Streck cfDNA BCTs particularly valuable for multi-center clinical trials, translational research, and drug development programs requiring standardized, reproducible liquid biopsy analysis across collection sites.

The shift toward liquid biopsies in clinical and research oncology has highlighted the critical importance of reliable pre-analytical sample handling. The quality of circulating tumor DNA (ctDNA) analysis is highly dependent on the initial steps of blood collection and stabilization. Without proper stabilization, white blood cells can lyse during shipment and storage, releasing large amounts of genomic DNA (gDNA) that dilutes the already scarce ctDNA fragments and compromises assay sensitivity [49]. Streck's Cell-Free DNA Blood Collection Tube (BCT) represents a significant innovation in this field, specifically designed to maintain sample integrity from the point of collection through transportation and processing. This application note provides a detailed evaluation of Streck stabilization tubes, comparing their performance against alternative systems and outlining standardized protocols for their implementation in ctDNA research.

Streck offers a portfolio of blood collection tubes designed to stabilize various analytes for liquid biopsy applications. The specifications and intended uses of their primary tubes relevant to ctDNA research are summarized in Table 1.

Table 1: Key Streck Stabilization Tubes for ctDNA Research

Product Name	Stabilized Analytes	Stabilization Duration & Conditions	Primary Applications	Regulatory Status
Cell-Free DNA BCT [9]	Cell-free DNA (cfDNA), Circulating Tumor Cells (CTCs)	cfDNA: Up to 14 days (6°C to 37°C) [9].CTCs: Up to 7 days (15°C to 30°C) [9].	Preserves cfDNA profile and minimizes gDNA contamination for research and diagnostic assays [9].	Available as RUO (Research Use Only) and CE-IVD/IVD [9] [23].
Nucleic Acid BCT [12]	cfDNA, cell-free RNA (cfRNA), Extracellular Vesicles (EVs)	Up to 7 days at room temperature [12].	Maintains draw-time concentrations of multiple nucleic acid types for multi-omic liquid biopsy approaches [12].	For Research Use Only [12].
Cell-Free DNA BCT (IVD) [23]	Cell-free DNA (cfDNA)	Up to 7 days at room temperature [23].	Intended for use with approved NGS assays like Guardant360 CDx and Guardant Shield [23].	For In Vitro Diagnostic Use [23].

The core technology of Streck tubes involves a proprietary preservative reagent that inhibits white blood cell lysis and nuclease activity. This action is crucial for limiting the release of genomic DNA, which can overwhelm the signal from low-abundance ctDNA, and for minimizing the degradation of the target ctDNA fragments themselves [9]. This stabilization allows for cold-chain-free transportation and room-temperature storage, thereby eliminating the logistical burden and potential variability associated with immediate plasma processing required by traditional K₃EDTA tubes [49].

Comparative Performance Data

Independent, peer-reviewed studies have directly compared Streck Cell-Free DNA BCTs against other commercially available stabilization tubes. A key study provides a head-to-head comparison with Roche Cell-Free DNA Collection Tubes, offering critical quantitative data for researchers selecting appropriate collection devices.

Table 2: Comparative Analysis: Streck vs. Roche Cell-Free DNA BCTs

Parameter	Streck Cell-Free DNA BCT	Roche Cell-Free DNA Collection Tube
Study Design	Blood from healthy volunteers (n=20) stored at room temperature and processed at 5 time points [36].	Same as Streck [36].
Key Finding (DNA Concentration)	No significant change in median paired DNA concentration from Day 0 to Day 14 (p=0.26) [36].	Significant increase in DNA concentration from Day 0 to Days 7, 10, and 14 (p=0.01, p=0.046, p=0.0016) [36].
gDNA Contamination	Effective stabilization limits gDNA release over 14 days [36].	Samples showed increased gDNA contamination beyond 7 days [36].
Recommended Stability	Up to 14 days at room temperature for cfDNA [9].	Suitable for room temperature storage for a duration of less than 7 days [36].

This comparative data indicates that while both tubes are effective for short-term stabilization, Streck BCTs provide a longer window for sample processing without significant gDNA contamination, a vital factor for ensuring the integrity of samples in multi-center trials or those undergoing long-distance transportation.

Detailed Experimental Protocols

Protocol: Blood Collection and Processing for cfDNA Analysis using Streck Tubes

The following protocol, derived from published methodologies, ensures optimal recovery of high-quality cfDNA from Streck Cell-Free DNA BCTs [56] [45].

Workflow Overview: Blood Collection to cfDNA Analysis

Materials Required:

• Streck Cell-Free DNA BCT tubes (10 mL) [9]
• Plastic disposable transfer pipettes
• Centrifuge tubes (e.g., 15 mL conical tubes)
• Microcentrifuge tubes (2 mL)
• Cryogenic vials for plasma storage
• Refrigerated centrifuge
• cfDNA extraction kit (e.g., Qiagen Circulating Nucleic Acid Kit) [56]
• Quality control instruments (e.g., Agilent Bioanalyzer 2100, Qubit Fluorometer) [56]

Step-by-Step Procedure:

• Blood Collection: Draw venous whole blood directly into the Streck Cell-Free DNA BCT. Invert the tube 8-10 times immediately after collection to ensure complete mixing of the blood with the preservative reagent. Do not vortex [9].

• Storage & Transport: Store and transport the collected blood samples at room temperature (within the 6°C to 37°C range). Plasma separation should be performed within 14 days for optimal cfDNA preservation [9].

• Plasma Separation (Dual-Centrifugation):

  • First Spin (Cell Separation): Centrifuge the BCT at 800-2,000 g for 10 minutes at 4°C to pellet blood cells [56] [45].
  • Plasma Transfer: Using a disposable transfer pipette, carefully transfer the supernatant ( plasma) into a new centrifuge tube. Take care not to disturb the buffy coat or cell pellet.
  • Second Spin (Debris Removal): Centrifuge the collected plasma at a higher force of 12,000-16,000 g for 10 minutes at 4°C to remove any remaining cellular debris and platelets [56] [45].
  • Final Plasma Harvest: Transfer the clarified, cell-free plasma into new cryovials for storage or direct use.

• Plasma Storage: For biobanking, immediately freeze the plasma at -80°C. Avoid multiple freeze-thaw cycles, as more than three cycles can degrade nucleic acids and reduce detection efficiency [45].

• cfDNA Extraction: Extract cfDNA from plasma using a dedicated circulating nucleic acid kit. Both silica-membrane columns (e.g., QIAamp Circulating Nucleic Acid Kit) and magnetic bead-based methods are suitable, though studies note silica membranes may yield more ctDNA [11] [56]. Elute the cfDNA in a low-bind tube.

• Quality Control: Quantify the extracted cfDNA using a fluorescence-based method like the Qubit Fluorometer. Assess the fragment size distribution and profile using a high-sensitivity instrument such as the Agilent Bioanalyzer 2100. A successful extraction will show a dominant peak around 160-170 bp, characteristic of mononucleosomal cfDNA, with minimal high-molecular-weight gDNA contamination [56].

Protocol: Integrated Workflow for Lung Cancer Screening and MRD Detection

A study utilizing the HIFI (High-performance Infrastructure For MultIomics) method for lung cancer screening and minimal residual disease (MRD) monitoring provides a robust example of Streck tubes in a complex research workflow [56].

Workflow Overview: Integrated Multi-Omic Liquid Biopsy Analysis

Key Steps:

• Sample Acquisition: Blood is collected from participants (e.g., lung cancer patients and healthy controls) and stored in Streck Cell-Free DNA BCT tubes [56].
• cfDNA Processing: Plasma is separated via dual centrifugation, and total cfDNA is extracted using a kit such as the Qiagen Circulating Nucleic Acid Kit [56].
• Multi-Omic Analysis:
  • A portion of the cfDNA (e.g., 5 ng) is used to construct a library for low-pass whole-genome sequencing (WGS) at ~2.5x depth. This allows for the analysis of genome-wide features like copy number alteration and fragmentation profiles [56].
  • In parallel, a highly sensitive targeted method like circulating Single-Molecule Amplification and Resequencing Technology (cSMART2.0) is used to detect specific tumor-derived mutations [56].
• Data Integration & Machine Learning: The multi-omic features (from WGS and cSMART) are integrated using a machine learning algorithm (e.g., Support Vector Machine) to build a predictive model (the "LC Score" for lung cancer) [56].
• Application & Output:
  • For early screening, the model distinguishes cancer patients from healthy individuals with high specificity (96.3%) and a high negative predictive value (NPV of 99.92%) [56].
  • For MRD detection, the combined use of WGS and cSMART results post-surgery significantly improves detection sensitivity (73.7% at 97.3% specificity) compared to using either method alone [56].

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Key Reagents and Kits for ctDNA Workflows Using Streck Tubes

Item Category	Specific Product Examples	Function in Workflow
Blood Collection Tubes	Streck Cell-Free DNA BCT (RUO/CE-IVD) [9]Streck Nucleic Acid BCT [12]	Stabilizes cfDNA and other analytes (cfRNA, CTCs) at room temperature, preventing gDNA release and analyte degradation.
cfDNA Extraction Kits	QIAamp Circulating Nucleic Acid Kit (Qiagen) [56]Maxwell RSC ccfDNA Plasma Kit (Promega) [11]	Isolate and purify short-fragment cfDNA from plasma with high yield and purity, suitable for downstream sensitive applications.
DNA Quantification	Qubit dsDNA HS Assay Kit (Thermo Fisher) [36]Agilent Bioanalyzer 2100 (HS DNA kit) [56]	Precisely quantify and qualify cfDNA, assessing concentration and fragment size distribution to confirm sample integrity.
Downstream Analysis	Illumina NovaSeq 6000 for WGS [56]Droplet Digital PCR (ddPCR) [11]	Detect and characterize tumor-specific alterations in ctDNA, from genome-wide patterns to low-frequency point mutations.

Streck Cell-Free DNA BCTs provide a robust and reliable solution for stabilizing blood samples intended for ctDNA analysis. Comparative studies demonstrate their superior performance in preventing gDNA contamination over extended periods of up to 14 days at room temperature, offering greater flexibility for sample logistics compared to some alternatives [36]. The integration of these tubes into standardized, multi-step protocols for plasma processing and DNA extraction is fundamental to ensuring reproducible and analytically sensitive results. Furthermore, their successful application in advanced, multi-omic research workflows—such as the HIFI method for lung cancer—highlights their critical role in enabling the next generation of liquid biopsy assays for early cancer detection and minimal residual disease monitoring [56]. For researchers and drug developers, the adoption of Streck stabilization tubes mitigates key pre-analytical variables, thereby enhancing the reliability of ctDNA-based data in both foundational research and clinical trial settings.

Conclusion

Streck Cell-Free DNA BCT tubes provide a robust solution for stabilizing ctDNA by effectively preventing white blood cell lysis and genomic DNA contamination for up to 14 days at room temperature, thereby minimizing pre-analytical variability. This stability is fundamental for the reliability of liquid biopsy in oncology, enabling flexible sample logistics without compromising data integrity for sensitive downstream applications like mutation detection. For the research community, adopting standardized protocols with Streck tubes enhances the reproducibility of ctDNA studies. Future directions should focus on further harmonizing pre-analytical standards and validating these workflows for emerging applications in minimal residual disease detection and early-stage cancer drug development, as encouraged by recent regulatory guidance.

References

• 1. FDA drafts guidance on ctDNA - Streck [https://www.streck.com/blog/fda-drafts-guidance-on-ctdna/]
• 2. Performance of Streck cfDNA Blood Collection Tubes for ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166354]
• 3. Why cfDNA Has Caused A Revolution In Genetic Diagnostics [https://nonacus.com/why-cfdna-has-caused-a-revolution-in-genetic-diagnostics/]
• 4. What do we need to obtain high quality circulating tumor ... [https://www.sciencedirect.com/science/article/pii/S0009898121001893]
• 5. Performance comparison of blood collection tubes as liquid ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6818589/]
• 6. Pre-Analytical Evaluation of Streck Cell-Free DNA Blood ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10093569/]
• 7. Comparison of cell stabilizing blood collection tubes for ... [https://www.sciencedirect.com/science/article/abs/pii/S000991201500377X]
• 8. Comparison of Roche Cell-Free DNA collection Tubes® to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6593214/]
• 9. Cell-Free DNA BCT RUO & CE - Streck [https://www.streck.com/products/stabilization/cell-free-dna-bct/]
• 10. Roche Cell-Free DNA Collection Tube [https://sequencing.roche.com/global/en/products/group/cell-free-dna-collection-tube.html]
• 11. Improvement of the sensitivity of circulating tumor DNA-based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12332530/]
• 12. Stabilization - Streck [https://www.streck.com/products/stabilization/]
• 13. Evaluation of automatic cell free DNA extraction metrics ... [https://www.nature.com/articles/s41598-025-03508-4]
• 14. Nucleic Acid BCT - Streck [https://www.streck.com/products/stabilization/nucleic-acid-bct/]
• 15. AACR 2025 - Streck [https://www.streck.com/aacr-2025/]
• 16. Evaluating the influence of collection tubes and extraction kits ... [https://www.streck.com/evaluating-the-influence-of-collection-tubes-and-extraction-kits-on-mirna-recovery-in-cancer-biomarker-research/]
• 17. Comparison of Blood Collection Tubes from Three Different ... [https://www.sciencedirect.com/science/article/pii/S1525157817302040]
• 18. Comparison of Blood Collection Tubes from Three Different ... [https://pubmed.ncbi.nlm.nih.gov/28732213/]
• 19. Streck Cell-Free DNA BCT [https://www.abacusdx.com/molecular/streck-cell-free-dna-bct/]
• 20. Cell-Free RNA DNA Preservation and Downstream Solutions [https://norgenbiotek.com/liquidbiopsy/plasmaserum?srsltid=AfmBOopiFi-etTE6sO3e3r1quDDcNMdWeFF31AYooQL77ty1n9AEOprc]
• 21. Pre-Analytical Evaluation of Streck Cell-Free DNA Blood ... [https://www.mdpi.com/2075-4418/13/7/1288]
• 22. Impact of pneumatic tube system transport and blood ... [https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-0367/html?srsltid=AfmBOooaEH5Sv-wzVpWmHGjOYxLKmg-VwolzsbMj0dYPWqlF7ZXbcpr2]
• 23. Cell-Free DNA BCT - Streck [https://www.streck.com/products/stabilization/cell-free-dna-bct-ivd/]
• 24. Comparison of next generation sequencing, droplet digital ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9058207/]
• 25. Performance Comparison of Droplet Digital PCR and Next ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12062871/]
• 26. dPCR and NGS: Better Together? [https://www.qiagen.com/us/knowledge-and-support/knowledge-hub/science-matters/pcr-solutions/dpcr-and-ngs]
• 27. a systematic comparison of DNA library preparation kits for ... [https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-016-2757-4]
• 28. Optimization of Preanalytical Variables for cfDNA ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8285169/]
• 29. A comparative study of four cell-free DNA assays for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12217890/]
• 30. A Review of Circulating Tumor DNA (ctDNA) and the Liquid ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12032849/]
• 31. Standardized Workflow and Analytical Validation of Cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12293894/]
• 32. How to automate ccfDNA and cfRNA extraction [https://www.promega.com/resources/technologies/lab-automation-resource-center/how-to-automate-ccfdna-and-cfrna-extraction/]
• 33. Evaluation of automated techniques for extraction ... [https://www.nature.com/articles/s41598-022-27216-5]
• 34. Extraction of Cell-Free DNA: Evaluation of Efficiency, ... [https://www.sciencedirect.com/science/article/pii/S152515782400014X]
• 35. Comparative analysis of circulating tumor DNA stability In K3EDTA... [https://pubmed.ncbi.nlm.nih.gov/27129799/]
• 36. Comparison of Roche Cell-Free DNA collection Tubes® to ... [https://www.sciencedirect.com/science/article/pii/S235255171830101X]
• 37. Impact of Long-Term Plasma Storage on Cell-Free DNA ... [https://www.mdpi.com/2218-273X/15/7/927]
• 38. A translational protocol optimizes the isolation of plasma- ... [https://www.nature.com/articles/s41598-025-08366-8]
• 39. Monarch® Spin gDNA Extraction Kit [https://www.neb.com/en-us/products/t3010-monarch-spin-gdna-extraction-kit?srsltid=AfmBOorZCsV0FClDfQOCGL52UvZkZelEMfaqo82fq8jSSpWmEmgs_Vwi]
• 40. Impact of Long-Term Plasma Storage on Cell-Free DNA ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12292636/]
• 41. How to Ensure cfDNA Stability in Blood and Urine Samples [https://www.qiagen.com/us/knowledge-and-support/knowledge-hub/bench-guide/cell-free-dna-guide/handling-cfdna/preanalytical-handling-and-cfdna-stability]
• 42. Clinical Practice Guidelines for Pre-Analytical Procedures ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8548242/]
• 43. Detection and quantification of rare mutations with ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3111315/]
• 44. Functional DNA quantification guides accurate next ... [https://genomemedicine.biomedcentral.com/articles/10.1186/gm481]
• 45. Circulating tumor DNA laboratory processes and clinical ... [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1520733/full]
• 46. Liquid biopsy in cancer: current status, challenges and ... [https://www.nature.com/articles/s41392-024-02021-w]
• 47. Improvement of the sensitivity of circulating tumor DNA- ... [https://www.explorationpub.com/Journals/etat/Article/1002333]
• 48. Clinical Practice Guideline for Blood-based Circulating Tumor ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10813828/]
• 49. Why does stabilization matter? - Streck [https://www.streck.com/blog/why-does-stabilization-matter/]
• 50. Implementation of circulating tumor DNA (ctDNA) testing in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12356032/]
• 51. International society of liquid biopsy (ISLB) perspective on ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12164225/]
• 52. Impact of Tube Additives on Baseline Cell-Free DNA ... [https://www.mdpi.com/2813-9038/2/1/4]
• 53. Circulating tumor DNA to monitor treatment response in ... [https://www.nature.com/articles/s41698-025-00876-y]
• 54. Clinical Circulating Tumor DNA Testing for Precision Oncology [https://pmc.ncbi.nlm.nih.gov/articles/PMC10101787/]
• 55. Enhanced detection of circulating tumor DNA by fragment size ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6483061/]
• 56. Multi-omics integrated circulating cell-free DNA genomic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10102814/]